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Abstract 
 
EXPRESSION PROFILING AND FUNCTIONAL VALIDATION OF MICRORNAs 
INVOLVED IN SCHIZOPHRENIA AND BIPOLAR DISORDER 
By Albert H. Kim, B.S., M.S.  
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University.  
 
Virginia Commonwealth University, 2011 
Dr. Vladimir I. Vladimirov, M.D., Ph.D. 
Asst. Professor, Department of Psychiatry; VIPBG, School of Pharmacy  
 
MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate gene 
expression at both the mRNA and protein levels.  MiRNAs have been shown to affect neuronal 
differentiation, synaptosomal complex localization and synapse plasticity, all functions thought 
to be disrupted in schizophrenia.  We investigated the expression of 667 miRNAs (miRBase 
v.13) in the prefrontal cortex of individuals with schizophrenia (SZ, N = 35) and bipolar disorder 
(BP, N =35) using a real-time PCR-based Taqman Low Density Array (TLDA).  After extensive 
QC steps, 441 miRNAs were included in the final analyses.  At a FDR of 10%, 22 miRNAs were 
identified as differentially expressed between cases and controls, 7 dysregulated in SZ and 15 in 
BP.  Using in silico target gene prediction programs, the 22miRNAs were found to target brain-
specific genes contained within networks overrepresented for neurodevelopment, behavior, and 
SZ and BP disease development.   
  
 
 
 Given that miRNAs can bind to their targets with imperfect complementarity, 
computational prediction of true miRNA:mRNA interactions has been difficult and therefore, 
functional validation of miRNA:mRNA interactions has been relatively sparse.  Thus, it was the 
goal of this study to demonstrate biological functionality of miRNAs on their targets by 
evaluating transcriptional and translational levels of gene expression(real-time PCR, western 
blot) as well as determining miRNA target-site specificity (luciferase reporter gene assays).   We 
investigated two miRNAs, miR-132 and miR-137, both of which have been shown to regulate 
neuronal function and development, and are believed to be associated with schizophrenia from 
two distinct avenues of research, miR-132 from expression studies and miR-137 from genetic 
studies.  We demonstrated miR-132 down-regulates NTF3, DISC1, and GRIK5 at the transcript 
level and down-regulates GRIK5 at the protein level as well.  Furthermore, we demonstrated 
miR-137 down-regulates TCF4, CACNA1C, CDK6, ANK3, and ZNF804A at the transcript level, 
and down-regulates TCF4, CACNA1C, and CDK6 at the protein level.  Going further, we also 
demonstrated miR-137 binds specifically to target sites in the 3'-UTR of CACNA1C, TCF4, and 
CDK6, suggesting repression of these genes is directly mediated by miR-137.  In total, this study 
provides strong evidence that miRNA dysregulation may contribute to schizophrenia 
pathogenesis.      
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Introduction 
 
Schizophrenia and Bipolar Disorder 
 
Diagnosis 
Both schizophrenia (SZ, MIM 181500) and bipolar disorder (BP, MIM 125480) are 
common (lifetime prevalence of 0.5-1% and 0.8–2.6% respectively) and debilitating psychiatric 
illnesses posing a major burden on public health due to their early onset, non-fatal course, and 
for many patients, need for long-term care.  According to DSM-IV-TR, three diagnostic criteria 
must be met to be diagnosed with schizophrenia (American Psychiatric Association, 2000):  1) 
The presence of two or more characteristic symptoms for a significant portion of a one-month 
period including delusions, hallucinations, disorganized speech, grossly disorganized or catatonic 
behavior , and negative symptoms (blunted affect, alogia, avolition); 2) Social or occupational 
dysfunction for a significant portion of time since the onset of the disturbance; 3) Continuous 
signs of the disturbance persist for at least six months, including at least one month of symptoms.  
Bipolar disorder on the other hand, is a mood disorder that is divided into three specific subtypes 
according to DSM-IV-TR: 1) Bipolar I, which requires one or more manic episodes, 2) Bipolar 
II, no manic episodes but one or more hypomanic episodes and one or more major depressive 
episode, and 3) Cyclothymia, a history of hypomanic episodes with periods of depression that do 
not meet criteria for major depressive episodes.   
Etiology 
The etiology of SZ and BP is currently unknown, however several major hypotheses have 
emerged.  One of the most influential theories of schizophrenia etiology has been the dopamine 
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hypothesis, which holds that schizophrenia (or psychosis more generally) is the result of a 
functional excess of dopamine (DA) somewhere in the human CNS.  It is derived from the 
evidence that antipsychotic drugs antagonize dopamine binding and reduce psychotic symptoms1, 
2.  Like the dopamine hypothesis, the glutamate hypothesis developed from observing the effects 
of mind-altering drugs.  It was shown that recreational use or investigator administration of a 
single low dose of an NMDA receptor antagonist such as phencyclidine (PCP) or ketamine 
produces "schizophrenia-like" symptoms in healthy individuals and profoundly exacerbates pre-
existing symptoms in patients with schizophrenia3, 4.  Finally, the neurodevelopmental hypothesis 
posits that abnormalities during development can lead to the activation of pathological neural 
circuits during adolescence or young adulthood, resulting in the emergence of positive and/or 
negative symptoms5.   
While these hypotheses are generally accepted, in conjunction with environmental and 
developmental factors6-15 consistent evidence for a substantial genetic component16, 17 has been 
shown (heritability ~80%), with some shared between both diseases18-20.  Protein-coding genes 
have long been the focus of research in disease genetics, but efforts to identify replicable protein-
coding risk loci in SZ21, 22 and BP23 remain elusive.  Current genome-wide association (GWA) 
studies of ever increasing size have finally begun to identify and consistently replicate 
schizophrenia candidate genes19, 21, 22.  Yet, for several of the best supported SZ susceptibility 
loci such as the human leukocyte antigen (HLA) genes in the major histocompatibility (MHC) 
region, zinc-finger 804A (ZNF804A), and transcription factor 4 (TCF4), genetic association does 
not appear to reflect DNA variants with any obvious effect on protein structure.  
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MicroRNAs (miRNAs) 
 
Background 
MiRNAs are a large family of small non-coding RNAs that negatively regulate gene 
expression at both the mRNA and protein levels24, 25.  MiRNAs were first discovered in 
C.elegans when Ambros and colleagues observed that small RNA products from the 
heterochronic lin-4 gene regulated lin-14 gene expression by means of an RNA-RNA antisense 
pairing26.  However, not having homologs in other species, this RNA-based regulatory 
mechanism was thought to be unique to C.elegans and it was not until the let-7 miRNA was 
discovered with homologs in humans and Drosophila, did this new class of RNA molecules gain 
acceptance27.  Since then, miRNAs have been shown to play key roles in diverse regulatory 
pathways28, including hematopoietic cell differentiation, apoptosis, cell proliferation, and organ 
development, as well as being linked to a number of human diseases ranging from cancers 
(“oncomirs”)29, 30 to autism31. 
Genomics 
 MiRNA genes are estimated to comprise approximately one percent of the predicted 
genes in worms, flies, and humans32.  To date, 1100 human miRNA genes are annotated in the 
miRNA registry33, with over one-third of human genes being predicted targets.  It was initially 
thought that most human miRNAs came from regions of the genome quite distant from 
previously annotated genes, implying that they are generated as independent transcriptional 
units.  However, recent analyses of miRNA gene locations showed that the large majority of 
miRNA genes are located within intronic regions of protein coding genes34 (Figure 1A), the 
expression of which largely coincides with the transcription of the host gene35.  In this way, 
  
4 
 
regulatory scenarios are easy to imagine in which such coordinated expression could be useful.  
The remaining miRNA genes 
are found in intronic regions 
of non-coding transcriptional 
units, ~10%, and exons of 
protein coding transcriptional 
units, the processing of which 
is dependent on alternative 
splicing, ~10%(Figure 1B).  
 
Processing 
MiRNAs are initially transcribed by the normal cellular machinery to yield a large RNA 
transcript (~1000nt) containing an extended stem-loop structure called a primary miRNA or pri-
miRNA.   This pri-miRNA transcript can encode a single miRNA (monocistronic) or several 
miRNAs (polycistronic).  Two subsequent processing events then lead to the functional, mature 
miRNA in animals.  First, the RNase-III enzyme, Drosha, coupled with the dsRNA binding 
protein DGCR8 (DiGeorge Syndrome critical region 8), cleaves the pri-miRNA into a smaller 
(~70nt) hairpin precursor miRNA or pre-miRNA, which gets exported from the nucleus via a 
Ran-GTP dependent transporter.  It is noteworthy that DGCR8 is one of several genes that is 
deleted in DiGeorge syndrome, the clinical manifestations of which range from schizophrenia to 
congenital heart defects36.  It has also been shown that DGCR8 provides specificity for Drosha 
cleavage, without which non-specific cleavage and degradation of the pri-miRNA occurs32.  
Once in the cytoplasm, a second RNase-III enzyme, Dicer, cleaves the loop structure of the pre-
Figure 1: Genomic location of miRNAs.  Adapted from Kim et 
al., Nature Reviews Molecular Cell Biology, 2009. 
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miRNA, resulting in a ~22bp double-stranded miRNA.  Subsequent events concerning the 
dissociation of this duplex, degradation of the passenger strand, and incorporation of the active 
mature miRNA (~22nt) into the RNA-induced silencing complex (RISC) are largely unknown.  
However, studies suggest that the 
strand with the less 
thermodynamically stable 5’ end 
gets incorporated into the RISC37, 
38.  This active RISC complex, 
consisting of the miRNA and 
Argonaute (Ago) proteins (Ago 
1-4 in mammals), then directs 
either translational repression or 
site-specific cleavage of target 
mRNAs depending on the degree 
of complementarity to its target.   
Binding of miRNA–RISC to a 
partially complementary mRNA 
results in silencing through the inhibition of translation and subsequent degradation of mRNA by 
catabolism within processing bodies (P-bodies)39.  On the other hand, direct cleavage or “slicing” 
of mRNA is solely catalyzed by Ago240 and requires perfect or near-perfect complementarity 
between the miRNA and the target41. (An overall schematic of miRNA processing is shown in 
Figure 2).  
 
Figure 2: Schematic of miRNA processing.  Adapted from 
Filipowicz et al., Nature Reviews Genetics, 2008. 
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Mechanism of miRNA binding 
Most miRNAs in animals are thought to function through imperfect base-pairing to the 
3’-untranslated region (3’-UTR) of the target mRNA27, 42, 43.  The mismatch between a miRNA 
and its target site can take on different configurations, with a central unpaired bulge in either the 
miRNA or target mRNA strand, or both.  Studies of how target site sequence and 
complementarity influence repression reveal that residues in the 5’ portion of the miRNA 
(residues 2-8, the “seed sequence”) are most important44, 45, with the degree of repression being 
dependent on the stability of pairing in this region.  Other less common mechanisms that have 
been described include 1) “canonical” sites, which show good base-pairing at the 5’ and 3’ ends, 
and 2) “3’ compensatory” sites which show weak 5’ base-pairing and depend on a strong 
pairing at the 3’ end.  Given that miRNAs require only minimum binding by a short seed 
sequence, it is not surprising that microarray studies reveal that a single miRNA can target 
hundreds of messenger RNAs46, suggesting that miRNAs can have pleiotropic effects on cellular 
processes.  Most miRNAs control mRNA stability and translation by binding to sequence motifs 
in the 3’-UTR of target mRNAs47, 48.  Although the majority of miRNA:mRNA interactions 
require perfect complementarity at the seed region, there are some exceptions to this rule, which 
complicates miRNA target predictions49.   
 
Principles of miRNA Target Prediction 
 Given that few miRNAs bind with perfect complementarity to their targets, much effort 
has been put toward devising a genome-wide computational search that captures most of the 
regulatory targets without bringing in too many false-positive predictions.  Current prediction 
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methods are diverse, and all have room for improvement, however a general agreement has 
emerged on three important criteria44, 50-52.  The first criterion is strong binding of the 5’ seed 
sequence (nucleotides 2-7) of the mature miRNA to the 3’-UTR sequence of the target gene.  
The second criterion is assessing the thermodynamic properties of the miRNA:mRNA duplex by 
calculating the free-energy (ΔG) of the putative interaction, i.e. a lower ΔG indicating the 
binding of the miRNA to mRNA is stronger.  Finally, the third criterion is conservation of the 
miRNA target site among different species.  Several prediction programs are currently available 
that follow these major criteria, the more prominent or established being: miRanda53, 
TargetScan54, PicTar55, PITA56, RNAHybrid57, RNA2258, DIANA-MicroT59, MicroInspector60, 
miTarget61, miRTarget262, and NBmiRTar63.   All 11 of these algorithms has been compiled into 
a single database, miRecords64, which allows the user to search all databases simultaneously.          
miRNAs in Schizophrenia and Bipolar Disorder  
 A growing number of miRNAs are discovered every year and approximately two-thirds 
are expressed in brain65 where they have been shown to be involved in maintaining brain 
function66-69.  In vitro studies demonstrate that miRNAs are localized to the synaptosomal 
complex70 where they affect neuronal differentiation71 and modulate synapse plasticity72, 
processes which have been implicated in SZ and BP73, 74.  Thus, miRNAs are likely candidates in 
neurodegenerative disorders and studies have attempted to evaluate the impact of miRNAs in SZ 
etiology at both genetic75-77 and expression77-79 levels.  
Expression Studies 
Only a handful of miRNA expression studies in schizophrenia have been performed to 
date.  Perkins80 and co-workers were the first to broadly assess differential expression of 
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miRNAs in schizophrenia cases versus controls (Harvard Brain Bank).  Using a custom miRNA 
microarray, they compared the expression of 264 human miRNAs in isolates from the post-
mortem dorso-lateral prefrontal cortex (DLPFC) of individuals with schizophrenia (n=13), 
schizoaffective disorder (n=2), and healthy controls (n=21).  The results showed 15 miRNAs 
were under-expressed (0.63-0.89-fold), and one over-expressed (1.77-fold) in cases compared to 
controls.  Subsequent real-time PCR analysis confirmed 7 of the under-expressed miRNAs—
miR-24, miR-26b, miR-29b, miR-30b, miR-30e, miR-92, and miR-195 (p<0.05).   
Beveridge81 and co-workers also used a custom microarray to analyze the expression of 
76 miRNAs in the postmortem superior temporal gyrus (STG) of 21 matched pairs of 
schizophrenia and non-psychiatric controls.  The results showed significant up-regulation of two 
miRNAs in cases, let-7g (1.8-fold) and miR-181b (2.8-fold).  Taking this result forward, the 
authors used in silico prediction algorithms to predict gene targets for miR-181b and compared 
the list of putative targets to genes already shown in microarray experiments to be down-
regulated in the same tissue.  Two genes were of particular interest due to their previous 
implications in synaptic dysfunction—the calcium sensor gene visinin-like 1 (VSNL1) and the 
ionotropic AMPA glutamate receptor subunit (GRIA2).  Both genes were shown to be suppressed 
with over-expression of miR-181b and were also shown to contain miR-181b target recognition 
elements in their 3’-UTRs via reporter gene assay.  Furthermore, in a follow-up study82, 
Beveridge and co-workers assessed miRNA expression in the STG and DLPFC of 21 matched 
cases and controls via microarray.  The authors reported a schizophrenia-associated global 
elevation of miRNA expression which corresponded with an increase in the microprocessor 
component DGCR8.  Several miRNAs were found to be up-regulated in both brain regions, the 
miR-15 family and miR-107 in the STG, and miR-181b and miR-16 in the DLPFC.           
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Genetic Studies 
In contrast to miRNA expression studies, a number of genetic studies have been 
conducted looking at miRNA involvement in schizophrenia.  Hansen6 and co-workers studied 
the association between schizophrenia and genetic variants of miRNA genes using a case-control 
study design on three Scandinavian samples.  Eighteen known SNPs within or near brain-
expressed miRNAs in three samples (Danish, Swedish and Norwegian: 420/163/257 
schizophrenia patients and 1006/177/293 control subjects), were analyzed.  Subsequently, joint 
analysis of the three samples was performed on SNPs showing marginal association.  Two SNPs 
rs17578796 in mir-206 and rs1700 in mir-198 showed nominal significant allelic association to 
schizophrenia in the Danish and Norwegian sample respectively (p = 0.0021 and p = 0.038), of 
which only rs17578796 was significant in the joint sample.    
 Feng83 and co-workers examined hemizygous miRNAs on the X-chromosome in males 
so that the full phenotypic consequences of a variant could be assessed without the possible 
mitigating effects of a wild-type allele.  59 miRNA genes on the X-chromosome were amplified 
and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test 
the hypothesis that ultra-rare mutations in microRNAs collectively contribute to the risk of 
schizophrenia.  Eight ultra-rare variants were identified in eight distinct miRNA genes (miR-18b, 
-505, -502, -188, -325, -660, -509, -510, and let-7f), six of the eight occurring in the mature 
sequence of the miRNA.  In vitro testing of the variants via luciferase assay revealed a functional 
alteration of miR-18b, miR-188, miR-502, and let-7f.      
Xu84 and coworkers investigated eight miRNAs identified to be differentially expressed 
in schizophrenia from previous studies and 15 of their experimentally validated target sites for 
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mutation screening and association studies in a Chinese case–control sample (456 cases/453 
controls).  The authors identified a new, potentially functional variant, ss178077483, located in 
the terminal loop of pre-mir-30e to be strongly associated with schizophrenia (P=0.00017, 
OR=4.952).  In addition, expression of mir-30e in peripheral leukocytes from cases and controls 
was significantly higher in cases (p=6.79e–7).  
Recently, in what is regarded as one of the largest genetic studies in schizophrenia to 
date, the Schizophrenia Psychiatric GWAS Consortium(PGC) examined the role of common 
genetic variation in schizophrenia based upon a combined GWAS broken into 2 stages:  Stage 1, 
a discovery sample of 21,856 individuals of European ancestry (EA; 9,394 cases and 12,462 
controls) and Stage 2, a replication sample of 29,839 independent subjects (8,442 cases and 
21,397 controls) (Gejman et al. in press).  After combining Stage 1 and 2 samples, the authors 
obtained genome-wide significant associations with schizophrenia for seven loci, five novel 
(1p21.3, 2q32.3, 8p23.2, 8q21.3, and 10q24.32-q24.33) and two (6p21.32-p22.1 and 18q21.2) 
previously implicated.  The strongest novel finding (p=1.6×10-11) for association to 
schizophrenia was to a genetic variant within the precursor of miR-137, a miRNA previously 
reported to regulate neuronal development85.  Moreover, four other schizophrenia loci achieving 
genome-wide significance in the study are predicted to be targeted by miR-137, suggesting miR-
137 gene dysregulation as a novel etiologic mechanism in schizophrenia. 
Significance 
 Given their abundance in the brain and implicated effects on brain development and 
function, miRNAs make particularly excellent candidates for studying psychiatric illnesses.  To 
date, the few studies that have attempted to profile miRNAs differentially expressed in 
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schizophrenia have used relatively small sample sizes (n<21), and have been limited to miRNAs 
believed to be expressed in the brain only (<264).  In contrast, our study included 35 patients 
with schizophrenia, 35 with bipolar disorder, and 35 controls, which is the largest sample 
profiled to date as well as being the first to profile miRNAs in bipolar disorder.  In addition, all 
667 known human miRNAs (at the time) were assayed, giving us an unbiased view of miRNAs 
dysregulated in disease.  Overall, studying the miRNA expression profiles in schizophrenia and 
bipolar disorder provides a foundation for understanding the complex etiology of each disease, 
helps to define and elucidate the genetic risks, and may ultimately serve as a reliable biomarker 
for disease progression and/or prognosis.  Our study may also clarify the discrepancies seen in 
the existing association data by assigning new functional roles for variants found in previous 
studies.  Finally, because miRNAs have the ability to regulate many genes at the same time, our 
study can also potentially bring together the numerous candidate genes reported to be associated 
with disease, ultimately leading to a unified biological explanation for the pathological processes 
underlying schizophrenia and bipolar disorder.   
 Due to the fact that miRNAs can bind to their targets with imperfect 
complementarity, computational prediction of miRNA:mRNA interactions has been plagued 
with false-positives.  Moreover, current widely accepted approaches for experimental validation 
of predicted miRNA:mRNA interactions are low-throughput and time and labor intensive.   
Therefore, only a limited number of miRNA:mRNA interactions have been validated so far.  
Thus, another goal of this study was to demonstrate biological functionality of miRNAs on their 
targets through a series of molecular-based approaches evaluating transcriptional and 
translational levels of gene expression (real-time PCR, western blot) as well as determining 
miRNA target-site specificity (luciferase reporter gene assays).  Our study investigated two 
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miRNAs, miR-132 and miR-137, both of which have been shown to regulate neuronal function 
and development, and have been associated with schizophrenia from two distinct avenues of 
research, miR-132 from expression studies and miR-137 from genetic studies.  We have 
successfully demonstrated miR-132 mediated down-regulation of neurotrophin 3 (NTF3), 
disrupted in schizophrenia 1 (DISC1), and ionotropic glutamate receptor kainate 5 (GRIK5) at 
the mRNA level, down-regulation of GRIK5 at the protein level, and that miR-132 directly binds 
to its predicted target site in the 3’-UTR of DISC1.  Additionally, we have successfully 
demonstrated miR-137 mediated down-regulation of transcription factor 4 (TCF4), voltage-
dependent calcium channel alpha-1A subunit (CACNA1C), cyclin-dependent kinase 6 (CDK6), 
ankyrin 3 (ANK3), and zinc finger 804A (ZNF804A) at the mRNA level, and down-regulation of 
TCF4, CACNA1C, and CDK6 at the protein level.  Furthermore, we have demonstrated that miR-
137 binds to specific target sites in the 3’-UTRs of TCF4, CACNA1C, and CDK6, suggesting 
miR-137 directly regulates these genes.    Implications drawn from this study support the 
hypothesis that dysregulation of miRNA function may lead to human disease.  
 
Materials and Methods 
 
Post-mortem brain tissue 
The Stanley Medical Research Institute (SMRI) provided 200mg of post-mortem brain 
tissue from the dorsolateral prefrontal cortex (Brodmann’s area 46)86. The sample demographics 
are described in Appendix 1.  Exclusion criteria included: (1) brain pathology, (2) history of pre-
existing CNS disease, (3) poor RNA quality, (4) IQ < 70, (5) age < 30 and (6) substance abuse 
within one year of death.  
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RNA Isolation and quantification 
All RNA was isolated as total RNA containing the small RNA fraction using the 
miRvana miRNA isolation Kit (Ambion, Austin, TX) following manufacturer’s 
recommendations.  RNA quality and concentration were subsequently measured on the 2100 
Bioanalyzer (Agilent, Santa Clara, CA) as well as on the Nanodrop 2000 (ThermoFisher 
Scientific, Waltham, MA).  Average RNA integrity number (RIN) for RNA isolated from cell 
culture was 9.8. 
For the Stanley post-mortem brain sample, RNA was isolated from 100mg of tissue using 
the miRvana miRNA isolation Kit (Ambion) following manufacturer’s recommendations.  The 
quality of RNA was assessed using the 2100 Bioanalyzer and average RIN for the entire sample 
was 7.2.  Tissue for one BP sample was not received and 1 control sample gave poor RNA 
quality, both of which were excluded from further analyses.   
Taqman Low-Density Array (TLDA) 
miRNA reverse transcription  
cDNA synthesis and expression detection were performed according to manufacturer’s 
protocols (Applied Biosystems, Hercules, CA).  Briefly, RNA was reverse transcribed using the 
miRNA reverse transcription kit in combination with the stem-loop Megaplex primer pool 
(ABI).  3 μl of total RNA (33.3 ng/μl) was combined with 0.8μl RT primer mix (10x), 0.8μl RT 
buffer (10x), 1.5 μl MultiScribe Reverse Transcriptase (10 U/μl), 0.2μl dNTPs with dTTP 
(0.5mM each), 0.9μl MgCl2 (3mM) and 0.1μl RNase inhibitor (0.25 U/μl) in a total reaction 
volume of 7.5μl.  Reactions were run on an Eppendorf Mastercycler (Eppendorf, Westbury, NY) 
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in a 384-well plate for 40 cycles at 16°C for 2 min., 42°C for 1 min., 50°C for 1 sec., and then 
held at 85°C for 5 min.   
miRNA Expression Detection  
Prior to detecting miRNA expression, the RT product was pre-amplified  following  
ABI’s recommendations,  allowing for increased detection sensitivity while preserving the 
miRNA87-89expression profile (Appendix 2).  The reactions were diluted with 75μl of 0.1X TBE 
and stored at -20°C. 9μl of product and 450μl of TaqMan PCR Master Mix, were combined with 
441μl nuclease free water, mixed and centrifuged for 30 sec. 100μl was loaded into each port of 
the appropriate 384 well TLDA array, centrifuged twice at 1200 rpm in a Sorvall Legend 
centrifuge (Thermo Scientific, USA), and sealed with a micro-fluidic card staker (ABI).  The 
arrays were run on the 7900HT Real-Time PCR System according to manufacturer’s protocol. 
Raw Cq values (RDML guidelines, http://www.rdml.org90) were calculated using the SDS 
software v.2.3 with automatic baseline settings at a threshold of 0.2.  
PCR expression normalization  
Under our experimental conditions, the three reference genes contained on the A and B 
TLDA arrays did not maintain a consistent ratio across samples (Appendix 3).  Therefore, we 
normalized our data using the median-polish procedure91, which has been used by others to 
evaluate global miRNA expression92.  A description of the method is given in Appendix 4.  
Quality Control (QC)  
Potential technical artifacts, such as plate effects93, were evaluated by plotting the sample 
profile correlations which were invariant under this normalization.  Two bands of low 
correlations were observed, which we interpreted as plate effects independent of diagnosis 
  
15 
 
(Appendix 5A).  Samples falling within these bands were excluded from further analyses as they 
also clustered separately from the main group (Appendix 5B).  Thus, the final sample was 
reduced to 29 SZ, 27 BP and 31 CONT. 
Statistical Methods—TLDA  
 The primary analyses were conducted using the rlm function in the R open-source 
statistical language (www.r-project.org) and the exploratory analyses were conducted using 
Robust Multiple Regression with Huber’s method as implemented in the NCSS 
(http://www.ncss.com) software package.  MiRNA variance was estimated using an F-test with 
corrected degrees of freedom and the Spearman (ρ) coefficient was used to estimate correlations 
of miRNA expressions.  Correction for multiple testing was accomplished using the Benjamini-
Hochberg94 False Discovery Rate (FDR) at 10%.  Gene targets for the differentially expressed 
miRNAs were predicted using the highly sensitive miRanda algorithm53 (V.3) with default 
parameters.  
Transfections 
6-well 
Transfections for gene expression assays were accomplished in 6-well plates.  One day 
before transfection, HEK 293 (Human Embryonic Kidney) and Be2C (neuroblastoma) cells were 
seeded in media without antibiotics at 600,000 cells per well to be 90-95% confluent at the time 
of transfection.  4ug of either mir-137 precursor or scrambled hairpin control plasmid 
(Genecopoeia Inc, Rockville, MD) was diluted into 250uL of Opti-MEM without serum.  In a 
separate tube, 10uL of Lipofetamine 2000 (Invitrogen, Carlsbad, CA) was diluted into 250uL 
Opti-MEM without serum and incubated for 5 minutes at room temperature.  After incubation, 
  
16 
 
the DNA and Lipofectamine dilutions were combined and incubated for 20 minutes at room 
temperature to allow complex formation to occur.  500uL of the DNA/Lipofectamine complex 
was then added to each well containing cells and 3mL of media without antibiotic.  The reactions 
were incubated at 37°C and harvested at 24 hours.  To increase accuracy and to reduce assay 
variability, each sample was transfected in triplicate. 
10cm Dish 
Transfections for western blotting were accomplished in 10cm dishes. One day before 
transfection, HEK 293 (Human Embryonic Kidney) and Be2C (neuroblastoma) cells were 
seeded in media without antibiotics at ~3.6x106 cells per well to be 90-95% confluent at the time 
of transfection.  12ug of either mir-137 precursor or scrambled hairpin control plasmid 
(Genecopoeia) was diluted into 1.5mL of Opti-MEM without serum.  In a separate tube, 35uL of 
Lipofetamine 2000 (Invitrogen, Carlsbad, CA) was diluted into 250uL Opti-MEM without serum 
and incubated for 5 minutes at room temperature.  After incubation, the DNA and Lipofectamine 
dilutions were combined and incubated for 20 minutes at room temperature to allow complex 
formation to occur.  3mL of the DNA/Lipofectamine complex was then added to each well 
containing cells and 12mL of media without antibiotic.  The reactions were incubated at 37°C 
and harvested at 24 hours.   
96-well Transfection      
The 96-well transfections were accomplished by following the alternate rapid protocol 
without pre-plating as outlined in Invitrogen’s Lipofectamine 2000 manual.  The following 
combination of miRNAs and targets were used to assess specificity of miRNA binding: 1) 180ng 
of mir-137 or miR-132 precursor (Genecopoeia) with 120ng of the target genes of interest, 2) 
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180ng of mir-137 or miR-132 precursor (Genecopoeia) with 120ng of mutated target genes of 
interest, 3) 180ng of mir-137 or miR-132 precursor (Genecopoeia) with 120ng of target genes of 
interest and 90nmol anti-miR-137 (Ambion), 4) 180ng of miR-377, an off-targeting miRNA 
precursor, with 120ng of target genes of interest, and 5) 180ng of miR-125a precursor 
(Genecopoeia) with 120ng of lin-4, a known miR-125a target gene (positive control).  The 
respective reactions were then diluted into 20uL of Opti-MEM without serum.  Next, for each 
well, 0.8uL of Lipofectamine 2000 (Invitrogen) was diluted into 24.2uL Opti-MEM without 
serum and incubated for 5 minutes at room temperature.  After incubation, the DNA and 
Lipofectamine dilutions were combined and incubated for 20 minutes at room temperature to 
allow complex formation to occur.  In the meantime, suspensions of HEK293 (Human 
Embryonic Kidney) or Be2C (neuroblastoma) cells were prepared to contain 120,000 cells in 
100uL of media without antibiotics.  The DNA-Lipofectamine complexes in each well were then 
mixed with 100uL of cells and incubated at 37°C and harvested after 24 hours.  To increase 
accuracy and to reduce assay variability, each sample was transfected in quadruplicate. 
Gene Expression Assays 
 cDNA was made from 1.5ug of RNA using the High Capacity cDNA Kit (ABI) 
according to manufacturer’s recommendations.  Gene expression assays were then performed by 
adding 0.25uL dH20, 0.25uL 20x Taqman Assay, 5.0uL Gene Expression Master Mix and 4.5uL 
cDNA diluted 1:10.  The reactions for each gene were run in triplicate in a 384-well format on 
the ABI 7900HT according to manufacturer’s recommendations.  PCR-efficiency for each 
reaction was assessed using the LinRegPCR95 program, which uses the raw real-time PCR data 
of each individual sample and performs a linear regression analysis to calculate starting 
concentrations of mRNAs and individual PCR efficiencies for each sample.  A reference house-
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keeping gene, importin 8 (IPO8), was also evaluated for each sample.  The gene expression data 
was then normalized using the 2(- ΔΔCt) method96 with IPO8 as the endogenous control.  The 
Student’s t-test was used to evaluate significant mean expression differences in GraphPad 
(GraphPad Software v.5.04, San Diego CA).     
Western Blot 
Protein was isolated from ~2x107 HEK293 or Be2C cells using 500uL of Mammalian 
Protein Extraction Reagent (MPER) following manufacturer’s protocol (Thermo Fisher).  Protein 
concentration was measure using the BCA Assay kit (Pierce) following the high range protocol 
for the Nanodrop 2000.  50ug of protein from each sample along with 10uL of the Precision Plus 
Dual Color Standard (Biorad) was loaded onto a 10% TGX gel (Biorad) in 1X Tris/Glycine/SDS 
buffer (Biorad) and run at 170V for 1 hour.  The proteins were then transferred to a PVDF 
membrane in 1X Tris/Glycine/SDS buffer with 20% methanol and ice pack at room temperature 
with constant stirring for 1 hour at 100V.  The membrane was then washed in 18mohm water 3 
times for 5 minutes and then blocked with Superblock (Thermo Fisher) for 1 hour at room 
temperature.  Once blocked, the primary antibody dilutions were made in Tris-Buffered Saline 
with Tween20 (TBST) and 10% blocking solution.  The primary antibody was incubated 
overnight at 4°C.  The membrane was then washed 5 times for 5 min with TBST.  The secondary 
antibody was then added in TBST with 10% blocking solution and incubated at room 
temperature for 1 hour.  The membrane was then washed 5 times for 5 min with TBST and 
developed using the SuperSignal West Pico (Pierce) kit according to manufacturer’s 
recommendations.  All antibodies were purchased from Santa Cruz Biotechnology, Inc (Santa 
Cruz, CA).  Concentrations for the antibodies used were as follows: GRIK5 1:250 primary (sc-
8915, goat polyclonal) and 1:20,000 donkey anti-goat secondary (sc-2020), CDK6 1:150 primary 
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(sc-271364, mouse monoclonal) and 1:10,000 goat anti-mouse secondary (sc-2005), TCF4 1:250 
primary (sc-101095, mouse monoclonal) and 1:10,000 goat anti-mouse secondary (sc-2005), 
CACNA1C 1:1,000 primary (sc-25686, rabbit polyclonal) and 1:40:000 goat anti-rabbit 
secondary (sc-2030), and α-tubulin  1:40:000 primary (sc-23948, mouse monoclonal) and 
1:20,000 goat anti-mouse secondary (sc-2005).   
3’-UTR Target Site Cloning and Mutagenesis 
 Approximately 100 base pairs (50bp up- and downstream of the predicted target site) was 
cloned into the pEZX-MT01 vector (Genecopoeia) using the AsiSI and XhoI restriction sites in 
the multiple cloning region downstream of the luciferase reporter gene.  All target-site cloning 
was performed by Genecopoeia, Inc.  Cloned target-site sequences can be found in Tables 6 and 
9 below.  Mutagenesis was performed using the QuickChange II Site-directed Mutagenesis Kit 
(Stratagene, La Jolla, CA) according to manufacturer’s protocol.  All clones were then sequenced 
by the Nucleic Acids Research Facility (NARF) at Virginia Commonwealth University.      
Luciferase Assay 
The luciferase assays were accomplished using the Luc-Pair miR Luciferase Assay 
(Genecopoeia) microplate procedure.  First, the media was aspirated and 100uL of Working 
Solution I (Solution I:Substrate I in a 1:200 ratio) was added to each well.  After 10 minutes, 
firefly luciferase activity was measured in a Wallac Victor II luminometer (ThermoFisher).  
Next, 100uL of Working Solution II (Solution II:Substrate II in a 1:200 ratio) was added to each 
well.  After 10 minutes, Renilla luciferase activity was measured.   Next, the ratio of firefly to 
Renilla luciferase was calculated (F/R) for each well and the average ratio for each quadruplicate 
was taken.  The average ratios were then normalized to the mock transfection, i.e. cells only.  
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Each set of miRNA and target experiment was performed at least three times and the Student’s t-
test (GraphPad) was used to calculate significant mean differences between each condition.     
 
Results 
TLDA 
Overall Performance 
Each cDNA sample (individual) was evaluated for the expression of 667 miRNAs. Of 
these, 226 miRNAs were excluded from further analyses due to lack of amplification, very low 
expression (Cq >35), or poor amplification efficiency across samples (missing expression values 
≥ 80%).  Thus, 441 miRNAs were included in all subsequent analyses and based on their 
expression, classified as highly (Cq 14-20), moderately (Cq 21-26), or low (Cq 27-34) expressed 
(Appendix 6).  Being a global miRNA evaluation, it was reasonable to observe that not all 
miRNAs were brain expressed.  
SMRI Demographic Covariates 
 Together with disease status, the SMRI provided additional information regarding 
potential confounders described in Appendix 7.  Upon inspection, only postmortem interval 
(PMI), refrigerated interval (RI) and antipsychotics showed deviation from a normal distribution, 
which were log-transformed to approximate normality.  In our analyses, none of the covariates 
showed consistent effects on miRNA expression. When fitting a regression model to a small 
number of samples, the number of estimated parameters cannot be large, therefore in all 
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analyses, only sex and pH were included as technical covariates as these were the only two 
showing a marginally significant effect on miRNA expression (Figure 15 in Appendix 7).     
Detection of differentially expressed miRNAs in SZ and BP cases 
 Our main objective was to evaluate expression differences between SZ and BP cases and 
controls for all known human miRNAs using the TLDA high throughput real-time qPCR 
approach.  The T-score distribution from the linear model showed deviation from the expected 
normal distribution (Figure 3) and after controlling the FDR at 10% , 22 miRNAs were identified 
as significantly dysregulated in SZ and BP (Table 1).  Notably, miR-7 and miR-212, which were 
previously reported to be dysregulated in the prefrontal cortex of individuals with SZ and 
schizoaffective disorder79, were also dysregulated in our sample.  
Figure 3: Q-Q plots of the distribution of T-scores within the (A) SZ and (B) BP groups.  T-
scores are obtained from the linear model. 
  
22 
 
Table 1: MicroRNAs differentially expressed in schizophrenia (SZ) and bipolar disorder (BP) compared to 
controls at FDR of 10%.  Bold=single-tube validated.  B(i)=regression coefficient, SE=standard error, +/- sign 
for T-values reflect up/down regulation respectively, Q-value=FDR measure. 
 
SZ cases 
Seven miRNAs were differentially expressed in the SZ group.  Of these, miR-34a, located on 
chromosome 1 (1p36.22), was the most significantly differentially expressed (p=0.00004) and in 
contrast to a previous study showing high expression97, this miRNA was moderately expressed in 
brain (average Cq = 21.8).  MiR-132 and -132* are processed from the same precursor and 
together with miR-212, form a cluster located on the reverse strand of chromosome 17 
(17p13.3).  MiR-132 and -212 were previously reported to be expressed in brain and our data 
confirm this observation98.  MiR-132 was highly expressed (average Cq=17.5) and hsa-mir-212 
was moderately expressed (average Cq of 23).  Both miRNAs were highly correlated 
(Spearman’s ρ = 0.87), supporting previous observations for coordinated expression of clustered 
miRNAs99-101.  MiR-132* however, was expressed at a lower level (average Cq=27.18) and was 
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less correlated with miR-132 (Spearman’s ρ = 0.65) and miR-212 (ρ = 0.47).  MiR-7 consists of 
three members located on three chromosomes; miR-7-1(9q21.32), miR-7-2 (15q21.6) and miR-
7-3 (19p13.3).  The miR-7 family showed moderate expression (average Cq=23.1), but since the 
mature sequence of these three miRNAs is identical, individual expression of each member could 
not be separated.  Finally, miR-544 was low (Cq=31.35) and miR-154* was moderately 
(Cq=26.31) expressed.  MiR-154* was the only miRNA showing expression differences in both 
SZ and BP.   
BP cases  
In the BP group, 15 miRNAs were observed to be differentially expressed.  Seven were over-
expressed and 8 were under-expressed (Table 1).  The over-expressed miRNAs were all 
moderately to highly expressed and showed significant correlation with each other (Table 2).  In 
contrast, the under-expressed miRNAs were moderately to low expressed and did not show any 
significant inter-correlations (Table 3).  In the BP group, only two miRNAs were modestly 
correlated with each other (Spearman’s ρ =0.35), miR-154* and -889, which cluster together on 
chr.14 (14q32.2).   
Table 2: Correlation matrix of miRNAs over-expressed in the BP group. Bold=Statistically significant 
Spearman's ρ coefficients at p<0.05. 
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Table 3: Correlation matrix of under-expressed miRNAs in the BP group.  Bold=Statistically significant 
Spearman's ρ coefficients at p<0.05. 
 
TLDA Validation 
 All 22 miRNAs identified as differentially expressed from the TLDA approach were 
subsequently validated in single-tube real-time PCR reactions.  One miRNA, miR-573, did not 
amplify and was therefore excluded from the validation analyses.  The remaining 21 miRNA 
expressions were normalized by the 2-ΔΔCt approach using RNU48 as an endogenous control.  
Eight miRNAs were successfully validated, 5 in SZ and 3 in BP (Table 1, bold).  The 
discrepancy between the multiplex and singly validated miRNA data could be explained by 
biological (heterogeneity) or technical (PCR conditions or pre-amplification) differences.  
Additional expression studies will be needed to address such issues.  However, many of the 
validated miRNAs reported here have also been previously reported in other studies using 
different platforms and/or samples. 
Analysis of miRNA variances   
 Although miRNAs tend to be dysregulated among individuals with SZ or BP, only a 
limited number of miRNAs (22/441 or 5%) demonstrated a consistent direction of altered 
expression, i.e. the same miRNA following a similar direction of expression across the entire 
sample.  This is not surprising considering the polygenic etiology of SZ and BP.  However, when 
miRNA variances between groups were compared, many of the miRNAs showing significant 
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variance differences (Appendix 8) were present in both disease groups (Figure 4), thereby 
supporting the previously observed shared genetic risk in SZ and BP19, 102.  
 
Figure 4: miRNAs with significant variance differences shared in schizophrenia and bipolar disorder. 
Exploratory analyses 
 Exploratory analyses were performed to assess the effect of disease duration103, 
smoking104, suicide105, and antipsychotic treatment on miRNA expression, as these traits were 
previously shown to affect expression of SZ candidate genes.  The only significant effect was 
observed for miR-193b* (p = 0.00002) when suicide was analyzed in interaction with disease.  
Antipsychotic treatment did not show any systematic effect on miRNA expression with miR-
218-2* (p = 0.000012) expression affected in the BP group only.  A probable explanation is that 
in the SMRI sample, antipsychotic treatment is reported as a generalized measure (fluphenazine 
equivalents).  Since different drugs may have different, if not opposing effects on miRNA 
expression, the individual drug effect is likely to be confounded.  
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In silico miRNA Target Prediction  
 As an initial evaluation, we used the most sensitive miRNA target prediction algorithm, 
miRanda106, to capture the most targets for the 22 differentially expressed miRNAs in the SMRI 
sample.  As a result, we identified 7,350 predicted gene targets for the seven miRNAs 
differentially expressed in the SZ group and 14,986 predicted gene targets for the 15 miRNAs 
differentially expressed in the BP group.  We then assessed the nature of these gene targets using 
the Ingenuity Pathway Analysis (IPA) web tool.  In IPA, we used our gene dataset as the 
reference set to minimize experimental or literature bias.  The most enriched functional group of 
genes amongst the differentially expressed miRNA targets were genes forming networks related 
to nervous system function and disease, including SZ and BP.  Therefore, knowing the 22 
differentially expressed miRNAs target disease-related genes, we were confident to move 
forward with our investigation of validating target genes.     
 Of the 22 differentially expressed miRNAs, we chose to focus on the schizophrenia-
related miRNAs as many (miR-7107, 108 , miR-21280,miR -13231, and miR-34a109, 110) have been 
implicated in the development and function of the nervous system as well as in previous miRNA 
expression studies in nervous system diseases.  Of the seven miRNAs differentially expressed in 
schizophrenia, we further investigated miR-132 due to it being high expressed and highly 
significant in our study as well as being implicated in other neurodevelopmental31 and 
degenerative disorders87 of the brain.  MiR-132 has also been shown to regulate neuronal 
morphogenesis111, 112, promote neurite outgrowth and spine formation113, 114, and is 
transcriptionally controlled by the neurotrophin BDNF (brain-derived neurotrophic factor), 
which is important for neuronal development, survival, synapse formation and plasticity115.   
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Bioinformatic Prediction of miR-132 Targets 
 Computational algorithms are prone to a high false-positive rate and the overall high 
sensitivity of miRanda, in particular, necessitates that additional steps are taken to reduce the 
type I error.  Thus, it has been recommended and successfully demonstrated116, that utilizing the 
intersection of at least two algorithms predicting the same binding site significantly reduces 
false-positives.  Therefore, we utilized the miRecords database64, which compiles the predictions 
from 11 established computational algorithms, to help derive the most plausible miR-132 
specific gene targets.  Using the intersection of at least two algorithms, 1,551 genes were 
predicted for miR-132.  From this list the following genes were selected based on prior 
biological evidence and/or strong association with schizophrenia  (Table 4).  Glutamate receptor, 
ionotropic, kainate 5 (GRIK5), Glutamate receptor, ionotropic N-methyl-D-aspartate 3A 
(GRIN3A), and glutamate receptor, ionotropic, N-methyl-D-aspartate 2B (GRIN2B) all code for 
ionotropic glutamate receptors, the dysfunction of which has been shown to be related to 
schizophrenia in multiple brain regions3, 117-121 .  Disrupted in schizophrenia 1 (DISC1) was first 
discovered when a chromosomal rearrangement that disrupts the gene was linked to 
schizophrenia in an extended Scottish family122 and has since been implicated in multiple 
association studies123, 124 as well as being shown to affect multiple processes in 
neurodevelopment125, 126.    Neurotrophin 3 (NTF3) belongs to a family of neurotrophins, 
including NGF (nerve growth factor) and BDNF (Brain Derived Neurotrophic Factor), and is an 
important regulator for survival, differentiation, and maintenance of nerve cells and acts to 
promote the growth and differentiation of new neurons127.   Circadian locomotor output cycles 
kaput (CLOCK) encodes a basic helix-loop-helix transcription factor that is essential for 
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circadian rhythm128 and has been shown to regulate dopaminergic transmission in the reward 
circuit129.  Furthermore, disruption of CLOCK in mice yields a behavioral profile similar to 
human mania (hyperactivity, decreased sleep, lowered depression-like behavior, lower anxiety, 
and an increase in the reward value for cocaine) 130.  Finally, cardiomyopathy associated protein 
(CMYA5) has recently been implicated in two genome-wide association studies of 
schizophrenia131,132.  
Table 4: Schizophrenia-related mir-132 target genes predicted by 2 or more programs in miRecords. 
 
miR-132 Target Gene Validation 
mRNA Expression  
To detemine whether miR-132 down-regulates the bioinformatically predicted target 
genes at the mRNA level, we transfected either a plasmid expressing the miR-132 hairpin or a 
scrambled hairpin control into HEK293 (human embryonic kidney) and Be2C (neuroblastoma) 
cell lines.  It is noteworthy that a plasmid expressing the miRNA hairpin was used as this allows 
for the miRNA to be processed by the normal cellular machinery.  The HEK293 cell line was 
chosen for the following reasons: 1) miR-132 is not endogenously expressed in the cells, 2) high 
Refseq Symbol Description Predicted by 
NM_001012958 DISC1 disrupted in schizophrenia 1 miRanda, PITA, RNAHybrid 
NM_002527 NTF3 neurotrophin 3 miRanda, PITA, RNAHybrid 
NM_133445 GRIN3A 
glutamate receptor, ionotropic, N-
methyl-D-aspartate 3A miRanda, PITA, RNAHybrid 
NM_600283 GRIK5 glutamate receptor, ionotropic, kainate 5 RNA22, RNAHybrid 
NM_004898 CLOCK circadian locomotor output cycles kaput PITA, RNA22, RNAHybrid 
NM_612193 CMYA5 cardiomyopathy associated protein RNA22, RNAHybrid 
NM_000834 GRIN2B 
glutamate receptor, ionotropic, N-
methyl-D-aspartate 2B 
miRanda, PITA, RNA22, 
RNAHybrid 
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transfection efficiency, and 3) the gene expression profile is similar to that of neurons133.   The 
Be2C cell line was chosen for the following reasons: 1) miR-132 is not endogenously expressed 
in the cells, 2) highest transfection efficiency among neuronal cell lines, and 3) it is a neuronal 
cell line, which is related to our tissue of interest.    After 24 hours, total RNA was isolated and 
gene expression was evaluated via real-time PCR.  For each condition, miR-132 or scrambled 
hairpin transfected, expression of an endogenous control gene was also measured to which the 
target gene expression values were normalized against.  Of the seven putative target genes tested, 
three were significantly down-regulated in the miR-132 transfected versus scrambled hairpin 
transfected conditions.   DISC1 was statistically significantly down-regulated in both 
HEK293(p=0.0001, n=27)  and Be2C(p=0.0019, n=27) cell lines.  NTF3 was also down-
regulated in both cell lines (p=0.0002, n=27 and p=0.0001, n=27) and GRIK5 was down-
regulated only in HEK293 (p=0.0001, n=27), as it was not endogenously expressed in Be2C cells 
(Figure 5).  The remaining four genes GRIN3A, GRIN2B, CLOCK, and CMYA5, were expressed 
in both cell lines but did not demonstrate statistically significant expression differences between 
treatment conditions.    
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Figure 5: Gene expression for miR-132 target genes.  NTF3 gene expression in (A) HEK 293 and (B) Be2C 
cells.  DISC1 gene expression in (C) HEK 293 and (D) Be2C cells.  GRIK5 gene expression in (E) HEK 293 
cells.  N=27 for each bar, error bars represent SEM.  Student’s t-test was used to test for statistical 
significance between scrambled hairpin (SH) and miR-132 conditions. 
 
Protein Expression 
 Having observed a miR-132 associated down-regulation of DISC1, NTF3 and GRIK5 at 
the mRNA level, we next evaluated whether the effect would be propagated at the protein level.  
To accomplish this, we transfected HEK293 cells with either miR-132 or a scrambled hairpin 
control and extracted whole cell protein lysates after 24 hours.  Western blots were then 
performed using alpha-tubulin as a loading control.  Densitometric quantification of the gel 
bands was then performed using the ImageJ program from the National Institutes of Health 
(http://rsbweb.nih.gov/ij/index.html).  Of the three genes tested, only GRIK5 was significantly 
down-regulated (p=0.0359) at the protein level in miR-132 transfected versus scrambled hairpin 
  
31 
 
transfected control (Figure 6).  No statistically significant differences in protein level were 
observed for NTF3 or DISC1.  
 Validation of miRNA:mRNA Interactions   
Demonstrating that miR-132 down-regulates DISC1and NTF3 at the mRNA level, and 
GRIK5 at both the mRNA and protein levels, we next sought to show miR-132 exerts its effects 
by binding to specific target-sites in the 3’-UTR of the respective target genes.  To assess this, 
we used miRecords64 to evaluate predicted miR-132 binding sites in the 3’-UTRs of DISC1, 
NTF3 and GRIK5, the results of which are presented in Table 5.  Three binding sites were 
predicted for DISC1, one of which, position 1160 in the 3‘-UTR, was predicted by five programs 
and was therefore used as the major miR-132 target site.  Four binding sites were predicted for 
NTF3, one of which, position 288 in the 3’-UTR, was predicted by five programs and was  
Figure 6:  Western blot data for GRIK5 protein expression.  (A) GRIK5 protein 
expression, (B) representative blot.  N=4 for each bar, error bars represent 
SEM. 
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Table 5: Predicted 3'-UTR binding sites for miR-132. 
miRNA RefSeq Gene Position in 3'-UTR Prediction Programs 
miR-132 NM_001012958 DISC1 1160 miRanda, PITA, DIANA-microT, 
RNAHybrid, RNA22 
miR-132 NM_002527 NTF3 288 miRanda, PITA, TargetScan, 
RNAHybrid, RNA22 
miR-132 NM_002088 GRIK5 2974 RNAHybrid, RNA22 
 
Table 6: 3'-UTR sequences cloned into the luciferase reporter construct.  WT=wild-type, Mut=Mutant, 
Bold=seed sequence, underline=site of mutation. 
  3'-UTR Sequence 
DISC1 WT 5' gttattctcaaattcagtcttccattcatctctccttcccttccctggcagacagacttctgca     gccactgggactgttggggtgaggaaaggcaagaaccgatgtttcattctctccct 3' 
DISC1 Mut 5' gttattctcaaattcagtcttccattcatctctccttcccttccctggcagacagacttctgca     gccactgggagacatggggtgaggaaaggcaagaaccgatgtttcattctctccct 3' 
NTF3 WT 5' gttttgtgatccggctctcaggagtcactctgtaaaatctgtgtacaccagtattttgcattcag     tattgtcaaggccatgactgttgttttagtaaacttgttaaaatc 3' 
NTF3 Mut 5' gttttgtgatccggctctcaggagtcactctgtaaaatctgtgtacaccag     tattttgcattcagtattgtcaaggccatgagacatgttttagtaaacttgttaaaatc 3' 
GRIK5 WT 5' gccccgccggcccccgggag ctggcggagccgagtgaccacgggcggggctgtgcg     ggcgcccggactgaccgaagggacggggcccgccccaggcc 3' 
GRIK5 Mut 5' gccccgccggcccccgggagctggcggagccgagtgaccacgggcgggggacagcg     ggcgcccggactgaccgaagggacggggcccgccccaggcc 3' 
 
therefore used as the major target.  Interestingly, only one site was predicted for GRIK5, position 
2,974 in the 3’-UTR by two programs, and therefore by default it was used as the major target 
site.  Once the putative target-sites were chosen for each gene, ~100bp fragment (~50bp up- and 
down-stream of the target site) was cloned into a reporter construct behind the luciferase gene.  
Mutant constructs were then made via site-directed mutagenesis, yielding a 4bp mutation in the 
target-site (Table 6).  All constructs were subsequently sequenced to ensure the fidelity of the 
wild-type and mutant sequences.  Next, to assess specificity of miRNA binding, the following 
combination of miRNAs and targets were transfected in quadruplicate in a 96-well plate: 1) mir-
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132 with wild-type target 3’-UTR, 2) miR-132 with mutant target 3’-UTR, 3) miR-132 with 
wild-type target 3’-UTR and anti-miR-132, and 4) miR-377 (an off-targeting miRNA) with wild-
type target 3’-UTR.  All reactions were performed in HEK293 cells and assayed 24 hours later.  
The mean ratio of firefly (F) over renilla (R) luciferase was then calculated for each sample and 
normalized against the F/R ratio from mock transfected cells (Lipofectamine only).     
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Figure 7: miR-132 target-site specificity.  Relative flourescence units (RFU) for miR-132 transfected with the 
DISC1 target and respective controls.  Stars represent statistically significant differences compared to miR-
132 with wild-type DISC1.  *p=0.0227, **p=0.0323, ***p=0.0221.  n=3 for each bar, error bars represent 
SEM. 
Statistically significant differences were observed (Figure 7) between miR-132 transfected with 
the wild-type DISC1 3’-UTR versus the mutated DISC1 3’-UTR (p=0.0227, n=3), wild-type 
DISC1 3’-UTR versus wild-type DISC1 3’-UTR with anti-miR-132 (p=0.0323, n=3), and wild-
type DISC1 3’-UTR versus wild-type DISC1 3’-UTR transfected with miR-377 (p=0.0221, n=3).  
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Thus, we conclude that miR-132 binds specifically to the DISC1 3’-UTR at position 1,160 and 
mediates down-regulation of luciferase gene expression, an effect which was alleviated by 
mutation in the seed sequence, addition of an anti-miR, and addition of an off-targeting miRNA.  
No significant differences were observed between miR-132 and GRIK5 or NTF3 3’-UTR target 
constructs, indicating miR-132 does not bind to target sites at positions 2974 and 288 in the 
respective genes.  However, mir-132 may bind to the other predicted binding sites in the 3’-UTR 
of GRIK5 and NTF3, or binding of other miRNAs may be required to work synergistically with 
miR-132 for proper inhibition of gene expression to take place.       
 MiR-137 as a Schizophrenia Candidate Gene 
 MiR-137 has been directly implicated in the regulation of adult neurogenesis85, dendritic 
development, and neuronal maturation134 and was also found to be one of three microRNAs with 
targets significantly enriched for association with schizophrenia in a study integrating genetic 
data from a GWAS with brain imaging as a quantitative trait135.  Moreover, in a recent genetic 
mega-analysis of unprecedented size (17,836 cases and 33,859 controls), the strongest novel 
finding for association with schizophrenia was to a variant within the precursor of miR-137, and 
four other schizophrenia loci achieving genome-wide significance in the study were predicted to 
be targeted by miR-137—transcription factor 4 (TCF4), calcium channel, voltage-dependent, L 
type, alpha 1C subunit (CACNA1C), cub and sushi multiple domains 1(CSMD1) and 
chromosome 10 open reading frame 26 (C10orf26) (Gejman et al. in press).  Furthermore, in the 
same study, CACNA1C and ankyrin 3 (ANK3) reached genome-wide significance in a joint 
analysis of 16,374 cases with schizophrenia or bipolar disorder and 14,044 controls.  
Interestingly, ANK3 is also a predicted target for miR-137.  Taken together, these data suggest 
miR-137 plays a role in schizophrenia pathogenesis.   
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miR-137 Target Gene Validation 
Gene Expression  
Given that predicted gene targets of miR-137 were found to be associated with 
schizophrenia, we chose to evaluate three of the top candidates implicated in the mega-analysis, 
TCF4136, CACNA1C137, and ANK3137 due to their prior association with SZ and BP.  In addition 
to these genes, we used miRecords to compile bioinformatically predicted target genes for miR-
137 and discovered two other schizophrenia candidate genes, CDK6 and ZNF804A were among 
the top predicted targets of miR-137 as well.  CDK6 has been shown to bind directly to Β-
Catenin 138, thereby acting to negatively regulate the Wnt-signalling pathway, which has been 
shown to play a central role in normal brain development and has been previously implicated in 
schizophrenia139-141 as well.  ZNF804A encodes a protein of unknown function, however it has 
been associated with schizophrenia and bipolar disorder in multiple studies142, 143, making it one 
of the most compelling schizophrenia candidate genes to date.    
To assess whether miR-137 down-regulates the putative target genes identified by genetic 
studies, we transfected either a plasmid containing the miR-137 hairpin or a scrambled hairpin 
control into HEK293 and Be2C cell lines.  After 24 hours, total RNA was isolated and gene 
expression was evaluated via real-time PCR.  All five putative target genes tested were 
significantly down-regulated at the mRNA level in the miR-137 transfected versus scrambled 
hairpin transfected conditions in both cell lines ( Figure 8).   TCF4 was statistically significantly 
down-regulated in HEK293(p=0.0359, n=27) and Be2C(p=0.0019, n=27), CACNA1C in 
HEK293(p=0.0162, n=27) and Be2C(p=0.00121, n=27), ANK3 in HEK293(p=0.0001, n=36) and 
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Be2C(p=0.0252, n=36), CDK6 in HEK293(p=0.0003, n=27)  and Be2C(p=0.0001, n=27), and 
finally ZNF804A in HEK293(p=0.0009, n=27) and Be2C(p=0.0001, n=27).    
 
Figure 8: miR-137 target gene expression in HEK 293 and Be2C cell lines.  SH=Scrambled Hairpin.  
Student’s T-test was used to calculate p-values.  N≥27 for each bar, error bars represent SEM. 
Protein Expression 
Having observed a miR-137 associated down-regulation of TCF4, CACNA1C, ANK3, 
CDK6, and ZNF804A at the mRNA level, we next tested whether the effect would be retained at 
the protein level.  To accomplish this, HEK293 cells were transfected with a plasmid expressing 
either the miR-137 hairpin or a scrambled hairpin control and whole cell protein lysates were 
extracted after 24 hours.  Western blots were then performed and of the five genes tested, 
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CDK6(p=0.0127), TCF4(p=0.0251) and CACNA1C(p=0.0164) were significantly down-
regulated at the protein level in miR-137 transfected versus scrambled hairpin transfected control 
(Figure 9).  However, no statistically significant difference in protein level was observed for 
ANK3 and no antibody was available for detection of ZNF804A.   
 
Figure 9: Western blot data for miR-137 gene targets.  (A) CDK6 protein expression (left), representative blot 
(right), (B) TCF4 protein expression (left), representative blot (right), (C) CACNA1C protein expression, 
representative blot (right).  N=3 for each blot, error bars represent SEM. 
miR-137 Target-site Specificity 
Given that miR-137 down-regulates ZNF804A and ANK3 at the mRNA level, and CDK6, 
TCF4 and CACNA1C at both the mRNA and protein levels, we next sought to demonstrate 
  
38 
 
specificity of miR-137 binding via reporter gene assays.  First, miRecords was used to complile 
predicted miR-137 binding sites in the 3’-UTRs of ZNF804A, ANK3, CDK6, TCF4, and 
CACNA1C, the results of which are presented in Table 8.  Seven binding sites were predicted for 
CDK6, one of which, position 7,140, was predicted by multiple programs and therefore was used 
as the major miR-137 target site.  Three binding sites were predicted for TCF4, one of which, 
position 4565 was predicted by multiple programs and therefore was used as the major target.    
Two binding sites were predicted for ZNF804A by one program, thus we chose position 4,660 as 
the major target based on better alignment score.  Only one binding site was predicted for 
CACNA1C and ANK3, position 1,410 and 230 respectively, and were therefore used as the major 
target sites for those genes.  Once the putative target sites were chosen for each gene, ~100bp 
fragment (~50bp up- and down-stream of the target site) was cloned into a reporter construct 
behind the luciferase gene.  Mutant constructs were then made via site-directed mutagenesis, 
yielding a 4bp mutation in the target site (Table 9).   
Table 8: Predicted 3'-UTR binding sites for miR-137. 
miRNA RefSeq Gene Position in 3'-UTR Prediction Programs 
miR-137 NM_001259 CDK6 7140 miRanda, PITA, TargetScan, PicTar 
miR-137 NM_003199 TCF4 4565 miRanda, PITA, TargetScan 
miR-137 NM_194250 ZNF804A 4660 PITA 
miR-137 NM_020987 ANK3 231 miRanda 
miR-137 NM_000719 CACNA1C 1410 TargetScan 
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Table 9: 3'-UTR sequences of miR-137 targeted genes cloned into the luciferase reporter construct.  
WT=wild-type, Mut=Mutant, Bold=seed sequence, underline=site of mutation. 
  3'-UTR Sequence 
CDK6 WT 
5'gtacccttacttgaaagtttctaatcttaagttttatgaaatgcaataatatgtatcagctagcaatatt 
    tctgtgatcaccaacaactctcagtttgatcttaaagtctgaataataaa 3' 
CDK6 Mut 
5'gtacccttacttgaaagtttctaatcttaagttttatgaaatgcaataatatgtatcagctaggttaatt 
    ctgtgatcaccaacaactctcagtttgatcttaaagtctgaataataaa 3' 
TCF4 WT 
5' cattacctgtttcccatctgtagttattcgatgaagtcatgtacatgaccgttctgtagcaataaat 
    gtgccatttttataaactgtttctgacacttgtttcatttcattttgcattgt 3' 
TCF4 Mut 
5' cattacctgtttcccatctgtagttattcgatgaagtcatgtacatgaccgttctgtaggttaaaat 
    gtgccatttttataaactgtttctgacacttgtttcatttcattttgcattgt 3' 
ZNF804A 
WT 
5' tttagacaaagctgatggcactatgttttgtatcatgttccttgaaactgtaaattcagtgaaaaatatc 
    tcttgcaataaatttttgttaactatttaa 3' 
ZNF804A 
Mut 
5' tttagacaaagctgatggcactatgttttgtatcatgttccttgaaactgtaaattcagtgaaaaatatc 
    tcttggttaaaatttttgttaactatttaa 3' 
ANK3 WT 
5' tgagccaatttacagagcatggaaatcactttcatttccggattggcgcgtgtgcaatt 
    agcaatgcagtgtatatacaagaagccatgctgttaacagttta 3' 
ANK3 Mut 
5' tgagccaatttacagagcatggaaatcactttcatttccggattggcgcgtgtggttat 
    agcaatgcagtgtatatacaagaagccatgctgttaacagttta 3' 
CACNA1C 
WT 
5' tctgcttctgaaacgggaatcagtaactctttgcattttctgtcccacaagatatgc 
    aaaaacaatgcaataatattcatttaaaaatacaattgtgagttgtgttggca 3' 
CACNA1C 
Mut 
5' tctgcttctgaaacgggaatcagtaactctttgcattttctgtcccacaagatatgc 
    aaaaacaatggttaaatattcatttaaaaatacaattgtgagttgtgttggca 3' 
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Next, we transfected the following combination of miRNAs and targets in quadruplicate 
in a 96-well plate to assess specificity of miRNA binding: 1) mir-137 with wild-type 3’-UTR, 2) 
miR-137 with mutant 3’-UTR 3) miR-137 with wild-type 3’-UTR and anti-miR-137, and 4) 
miR-377, an off-targeting miRNA with wild-type 3’-UTR.  All reactions were performed in 
HEK293 cells and assayed 24 hours later.  The results are shown in Figure 10.   
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Figure 10: miR-137 target-site specificity.  (A) CDK6—Statistically significant differences were observed 
between miR-137 transfected with the wild-type CDK6 3’-UTR versus the mutated CDK6 3’-UTR (p=0.0264, 
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n=3), wild-type CDK6 3’-UTR versus wild-type CDK6 3’-UTR with anti-miR-137 (p=0.0308, n=3), and wild-
type CDK6 3’-UTR versus wild-type CDK6 3’-UTR transfected with miR-377 (p=0.0052, n=3).  (B) 
CACNA1C— Statistically significant differences were observed between miR-137 transfected with the wild-
type ZNF804A 3’-UTR versus the mutated ZNF804A 3’-UTR (p=0.004, n=3), wild-type ZNF804A 3’-UTR 
versus wild-type ZNF804A 3’-UTR with anti-miR-137 (p=0.0052, n=3), and wild-type ZNF804A 3’-UTR 
versus wild-type ZNF804A 3’-UTR transfected with miR-377 (p=0.0012, n=3).  (C) TCF4— Statistically 
significant differences were observed between miR-137 transfected with the wild-type TCF4 3’-UTR versus 
the mutated TCF4 3’-UTR (p=0.0186, n=3), wild-type TCF4 3’-UTR versus wild-type CDK6 3’-UTR with 
anti-miR-137 (p=0.0228, n=3), and wild-type TCF4 3’-UTR versus wild-type TCF4 3’-UTR transfected with 
miR-377 (p=0.0311, n=3).  (D) CACNA1C— Statistically significant differences were observed between miR-
137 transfected with the wild-type CACNA1C 3’-UTR versus the mutated CACNA1C 3’-UTR (p=0.0463, n=3), 
wild-type CACNA1C 3’-UTR versus wild-type CACNA1C 3’-UTR with anti-miR-137 (p=0.0472, n=3), and 
wild-type CACNA1C 3’-UTR versus wild-type CACNA1C 3’-UTR transfected with miR-377 (p=0.0261, n=3).  
Significant down-regulation of luciferase expression was observed for miR-137 binding to 
specific sites in the 3’-UTRs of CDK6, ZNF804A, CACNA1C, and TCF4, an effect which was 
alleviated by mutation in the seed sequence, addition of an anti-miR, and addition of an off-
targeting miRNA.  Thus, we have demonstrated miR-137 binds specifically to 3'-UTR target 
sites in CDK6 (position 7,140) , ZNF804A (position 4,660), TCF4 (position 4565), and 
CACNA1C (position 1,410).  Furthermore, having observed down-regulation at both the mRNA 
and protein levels for CDK6, CACNA1C, and TCF4, we conclude that miR-137 can regulate the 
expression of these genes by binding to specific sites in the 3'-UTR.  No statistically significant 
difference was observed for miR-137 binding to the 3’-UTR target site in ANK3, indicating miR-
137 does not exert its effect via the target site cloned.   
 
Discussion 
MiRNA Expression Profiling 
miRNAs have key roles in regulating gene expression and brain development, and thus are 
likely genetic factors contributing to the etiology of psychiatric disorders.  In the first part of this 
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study, we conducted an evaluation of miRNA expression in postmortem tissues from SZ and BP 
cases.  Of the total number of analyzed miRNAs (N=441), we identified seven to be 
differentially expressed in SZ and 15 to be differentially expressed in BP, which constitutes ~5% 
of miRNAs studied.  Similar observations have been made in other studies of SZ79and autistic92 
cases, respectively.  Although relatively few miRNAs showed consistent unidirectional 
expression differences (22miRNAs, ~5%) between cases and controls, we did observe a large 
number of miRNAs with significant variance differences in SZ and BP, many of which were 
shared by both disease groups.  Thus we, as others92, 144, argue that the development of SZ and 
BP is likely to reflect two classes of miRNAs: the first class consisting of miRNAs showing 
consistent unidirectional expression across all cases in the disease groups, and the second class 
showing much greater individual variability of expression. 
Several studies have attempted to address differential expression of miRNAs in the 
etiology of SZ.  Perkins and colleagues79 were the first to evaluate miRNA expression in a 
postmortem brain sample consisting of 13 individuals with SZ and 2 individuals with 
schizoaffective disorder. They identified 16 miRNAs dysregulated in cases, two of which, hsa-
miR-7 and -212, were also differentially expressed in our study.  In two separate studies, 
Beveridge and colleagues observed 26 differentially expressed miRNAs in the dorso-lateral 
prefrontal cortex (DLPFC) of SZ cases78, 82, one of which, miR-7, was differentially expressed in 
our study.  Finally, in a study of SZ and autistic cases92, 28 miRNAs were shown to be 
dysregulated in cases, two of which, miR-7 and -132, were differentially expressed in our study.  
In addition to being dysregulated in SZ and autistic cases, miR-7 has been shown to be 
involved in the development of Parkinson’s disorder by repressing the expression of alpha 
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synuclein (α-Syn), a protein that accumulates in the nigral dopaminergic neurons108.  MiR-7 was 
also shown to be involved in the development of glioblastoma by repressing the epidermal 
growth factor receptor (EGFR) gene and the AKT1 signaling pathway145.  The repressing effect 
of miR-7 on AKT1 is noteworthy since AKT1 has been shown to be associated with BP146 
disorder and with SZ across multiple populations147-151.  
MiR-132 and miR-212 form a cluster located on the reverse strand of chromosome 17 
(17p13.3).  Transcription of this cluster has been shown to be up-regulated by the neurotrophin 
BDNF, brain-derived neurotrophic factor112, 115.  Neurotrophins are growth factors that are 
important for neuronal development and survival as well as synapse formation and plasticity127.  
MiR-132 has also been implicated in regulating neuronal morphogenesis112 via the regulation of 
p250GAP111, 114 and over-expression of miR-132 has been found to promote neurite outgrowth 
and dendritic spine formation, whereas inhibitors of miR-132 reduced these processes113, 152.  
Furthermore, MECP2 (methyl CpG binding protein 2) and SIRT1 (sirtuin 1), both of which can 
act as transcriptional regulators, have been suggested to be miR-132 targets153, 154.  MECP2 is 
required for maturation of neurons and mutations in MECP2 underlie Rett syndrome, an X-
linked neurodevelopmental disorder.  Lastly, mir-132 and -212 expressions have been reported to 
be dysregulated in Alzheimer’s disease155, suggesting a broader impact of these miRNAs on 
diseases of brain development.   
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Functional Validation of miRNA Targets 
miR-132 
 We focused on miR-132 because it was highly expressed and highly significant in our 
study, has been shown to be involved in several neuronal processes, and has been implicated in 
other miRNA expression studies of autism and Alzheimer's.  We used bioinformatic algorithms 
to predict potential gene targets for miR-132, and chose to further investigate seven genes due to 
their biological relevance to the etiological hypotheses of schizophrenia and/or prior strong 
association with schizophrenia.  Of the seven genes, three were significantly down-regulated at 
the mRNA level in miR-132 over-expressed versus scrambled hairpin control, NTF3, DISC1 and 
GRIK5, suggesting miR-132 affects these transcripts.  Taking these genes forward for 
investigation at the protein level, only GRIK5 was observed to be significantly down-regulated.  
We also sought to demonstrate that miR-132 binds specifically to target-sites in the 3’-UTRs of 
NTF3, DISC1 and GRIK5.  After cloning the putative miR-132 target sites and respective 
mutants into a luciferase construct, we observed a significant down-regulation of luciferase 
activity compared to controls for DISC1 only, indicating miR-132 binds specifically at position 
1,160 in the DISC1 3’-UTR.  Interestingly, we observed down-regulation of DISC1 at the mRNA 
level and demonstrated that this effect can be mediated by miR-132 binding to a specific target-
site in the 3’-UTR.  However, we were unable to detect down-regulation of DISC1 at the protein 
level, which can be reconciled by, 1) DISC1 protein is not down-regulated at an appreciable 
level, i.e. a small change in protein that may not be detected by Western blot, or 2) an alternative 
mechanism exists that compensates for DISC1 expression.   
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  miR-132 and NTF3 
 Neurotrophins are important regulators for survival, differentiation, and maintenance of 
nerve cells and act to promote the growth and differentiation of new neurons127.  NTF3 belongs 
to a family of neurotrophins, which include NGF 
(nerve growth factor) and BDNF (Brain Derived 
Neurotrophic Factor), and has been shown to 
encourage axon elongation and branching156 by 
inhibition of GSK-3β via the phophatidylinositol-
3-kinase (PI3K)/Akt pathway (Figure 11).  
Similarly, in a reverse genetic study, Ma et al. 
found that ablation of NTF3 in the mouse 
neocortex resulted in reduction of a set of axonal 
bundles projecting from the thalamus through 
the cortical white matter.  These bundles included thalamo-cortical axons that normally establish 
connections with the retrosplenial and visual cortex157.  The retrosplenial cortex is part of the 
cingulate cortex and is implicated in the recall of episodic information and is one of several brain 
regions that produce anterograde amnesia when damaged.  Taken together, miR-132 related 
down-regulation of NTF3 mRNA, particularly during development, may prevent axon elongation 
and branching and reduce thalamo-cortical connections leading to the manifestation of symptoms 
later in life.  Thus, although miR-132 mediated down-regulation of NTF3 protein was not 
observed in our study using cell lines, one might be able to observe a down-regulation in an 
animal model focusing on neurodevelopment.            
miR-132 and DISC1 
Figure 11: Schematic of the role of neurotrophins NTF3 
and BDNF on the PI3K/Akt pathway.  Adapted from  
Yoshimura et al., Cell, 2009.  
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 Linkage and association studies in multiple populations have identified DISC1 as s 
susceptibility factor for schizophrenia122-124.  Although the function of DISC1 is unclear, multiple 
studies indicate a role for DISC1 in the developing brain.  In a yeast-2-hybrid analysis, Ozeki et 
al. demonstrated DISC1 binds to NudE-like (NUDEL), a cytoskeletel protein essential for 
cortical development and axon growth126.  Failure of this interaction has been shown to result in 
inhibition of neurite outgrowth in vitro158 and abnormal cortical development in vivo159.  
Furthermore, observing DISC1 expression during mouse development, Schurov et al. reported 
the amount of DISC1 peaks in the mouse brain during the time of embryonic neurogenesis and 
again during puberty160, two critical time points implicated in the pathophysiology of 
schizophrenia161.     Thus, similar to NTF3, miR-132-mediated down-regulation of DISC1 may 
play a key role in schizophrenia pathology during development.  
miR-132 and GRIK5 
 Glutamate is the major excitatory neurotransmitter in the central nervous system.  Nearly 
half of the neurons in the brain, including all neurons that project from the cerebral cortex, are 
believed to use glutamate as their neurotransmitter.  Glutamate receptors are classified into two 
broad categories: ionotropic and metabotropic receptors.  Ionotropic glutamate receptors, which 
include NMDA, kainate, and AMPA subtypes, initiate rapid depolarization by facilitating 
sodium or calcium entry into neurons through channels formed by the receptor itself.  GRIK5 
codes for an ionotropic glutamate receptor in the kainate receptor family (Table 10). 
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Table 10: Ionotropic glutamate receptors.  Adapted from Dingledine et al. Pharmacol. Rev., 1999. 
 
The glutamate hypothesis of schizophrenia posits that the function of the N-methyl-D-aspartate 
(NMDA) receptor is compromised in disease.  This hypothesis came about due to the 
observation that NMDA receptor antagonists such as phencyclidine (PCP) and ketamine induced 
schizophrenia-like psychosis in normal volunteers and exacerbated psychotic symptoms in 
schizophrenic patients3, 162.  These data have been interpreted to suggest that NMDA receptor 
hypo-activity is associated with schizophrenia.   
However, it is not apparent whether NMDA receptor hypo-activity results from a primary 
defect in NMDA receptors or from dysfunction in one of the other three glutamate receptor 
families that may secondarily lead to low levels of NMDA receptor activity.  It has been shown 
that glutamate release from pre-synaptic kainate receptors can affect post-synaptic NMDA 
receptor-mediated neurotransmission163, 164.  In this way, dysfunction of the GRIK5 receptor 
could mimic abnormal NMDA receptor activity.  Furthermore, expression studies in post-
mortem brains have shown significantly lower levels of GRIK5 mRNA in several brain regions 
including the prefrontal cortex119, hippocampus120 and thalamus117.  Specifically, using in situ 
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hybridization, Meador-Woodruff et al. observed decreased GRIK5 mRNA expression in 
Brodmann areas 9 and 46, both of which correspond to the prefrontal cortex, with the latter being 
the same brain region used in our miRNA profiling study119.  In addition, Ibrahim et al. observed 
GRIK5 mRNA was significantly reduced in the centromedial nucleus of the thalamus, which is a 
major thalamic relay between prefrontal, cingulate, and other limbic cortical areas, and the 
dorsomedial nucleus of the thalamus, which projects primarily to the prefrontal cortex117.  Thus, 
given that we observed miR-132 was up-regulated in the prefrontal cortex (Brodmann area 46) of 
schizophrenic brains, and miR-132 down-regulated GRIK5 at both the mRNA and protein levels, 
we provide strong evidence for a role of miR-132 disrupting glutamatergic transmission in 
schizophrenia.  
 
miR-137 
 Although expression studies have not shown miR-137 to be differentially expressed in 
schizophrenia, in our study, miR-137 demonstrated significant variance differences in SZ 
compared to controls, with a trend toward over-expression (Figure 12).     
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Figure 12: Scattergram of miR-137 expression in the SMRI postmortem brain sample.  Horizontal line 
indicates mean expression value (Ct).   
 Several genetic studies of schizophrenia have implicated miRNAs to be associated with 
disease and recently, miR-137 was found to be the strongest novel finding in the largest genetic 
study of schizophrenia to date (Gejman et al. in press).  Additionally, predicted gene targets of 
miR-137 were also significantly associated in the study.  Thus, it was the goal of our study to 
validate the predicted interactions between a miRNA discovered by a genetic study, miR-137, 
and its predicted target genes.  We investigated five genes predicted to be targeted by miR-137—
TCF4, CACNA1C, ANK3, CDK6, and ZNF804A.  All five were significantly down-regulated at 
the mRNA level in miR-137 over-expressed versus scrambled hairpin control and three, 
CACNA1C, TCF4, and CDK6 were significantly down-regulated at the protein level as well.  
Going further, we also demonstrated that miR-137 binds specifically to target sites in the 3'-UTR 
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of CACNA1C, TCF4, and CDK6, suggesting that repression of these genes is directly mediated 
by miR-137. 
miR-137 and  TCF4  
  TCF4 belongs to to a subfamily of basic helix-loop-helix (bHLH) transcriptional 
regulators which have been shown to play important roles as neural progenitors in the developing 
nervous system165 and mammalian cortex166.  Two large genetic studies have implicated TCF4 as 
a promising candidate gene for schizophrenia.  Stefansson et al. reported the C allele of the TCF4 
rs9960767 polymorphism to be more frequent in patients with schizophrenia, leading to a 1.23-
fold higher risk for the disorder136.  This finding has been recently replicated in a mega-GWAS 
(Gejman et al. in press).  Quednow et al. further investigated the influence of the disease-
associated C allele on pre-pulse inhibition (PPI), an established endophenotype of schizophrenia, 
and found the schizophrenia-associated C allele to be strongly associated with reduced PPI167.  
PPI deficits have been implicated in the biological basis of schizophrenia and other 
neuropsychiatric disorders characterized by deficient suppression or ‘gating’ of irrelevant 
sensory, cognitive, or motor processes168.  In addition to being associated with schizophrenia in 
two large genetic studies, haploinsufficiency of the TCF4 gene has been shown to cause Pitt-
Hopkins syndrome, a neurodevelopmental disease characterized by severe mental retardation, 
epilepsy, facial dysmorphisms, and intermittent hyperventilation169-171.  In this way, mir-137 
mediated down-regulation of TCF4 may in part, contribute to the pathogenesis of schizophrenia. 
miR-137 and CDK6 
The Wnt signalling pathway has been shown to play a central role in normal brain 
development, cell fate determination, and synaptic plasticity172-174.  A schematic of the Wnt 
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signalling pathway is depicted in Figure 13.  Expression of genes in the Wnt signalling pathway 
have also been shown to be altered in schizophrenia.  Using immunohistochemical analysis of 
post-mortem brains, Miyaoka et al. observed signifcant increases in the number of Wnt-1 
immunoreactive cells in CA3 and CA4 regions of the hippocampus140.  In a similar study, Cotter 
et al. observed signifcant reductions of β-Catenin in the same hippocampal regions of 
postmortem brain tissue139.  Taken together, these observations point to a malfunction of β-
Catenin in schizophrenia, which in turn leads to a reactive increase in Wnt-1 expression.  CDK6 
has been shown to negatively regulate Wnt signalling by phosphorylating β-Catenin, thereby 
initiating its degradation138.  It has been proposed that CDK6 participates in a negative feedback 
loop which could serve to restrict the duration or spread of β-Catenin mediated signals.  Thus, 
miR-137- mediated down-regulation of CDK6 may disrupt the normal inhibition of β-Catenin-
mediated gene expression , i.e. miR-137 inhibits an inhibitor, leading to uncontrolled expression 
of genes involved in schizophrenia pathogenesis.   
 
Figure 13: Schematic of the Wnt signalling pathway.  (A) In the absence of Wnt receptor activation, B-
catenin is constitutively phosphorylated by GSK-3, leading to the degradation of B-catenin and inhibition of 
B-catenin-mediated gene transcription.  (B) Binding of Wnt to its receptor results in the formation of a 
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complex which phosphorylates GSK-3, preventing it from phosphorylating B-catenin.  B-catenin 
consequently escapes degradation and accumulates in the nucleus where it regulates transcription through 
interactions with DNA transcription factors.  Adapted from Freyberg et al.,  Am. J. Psychiatry, 2010. 
miR-137 and CACNA1C 
 Voltage-gated Ca2+ channels have a central role in neuronal function and are essential for 
converting electrical activity into biochemical events.  CACNA1C codes for the alpha 1C subunit 
of the L-type Ca2+ channel (LTC) and has been previously implicated as a risk factor for bipolar 
disorder137, and more recently for schizophrenia20 as well.  Genetic variation in CACNA1C has 
been associated with decreased working memory processing in the prefrontal cortex175 and a 
missense mutation in CACNA1C results in Timothy syndrome, which is characterized by multi-
organ dysfunction, including cardiac arrhythmias and cognitive abnormalities176.  Activation of 
LTCs have also been shown to specifically increase the expression of genes such as BDNF that 
are important for neuronal survival, learning, and adaptive responses in the nervous system177.  
Furthermore, a number of transcription factors essential for neuronal survival and plasticity such 
as CREB and MEF-2, have been shown to be dependent on Ca2+  fluxes through LTCs178 179.  
Given the important roles of LTCs in brain function, miR-137-mediated down-regulation of 
CACNA1C may lead to defects in calcium transmission in neurons, thereby contributing to 
schizophrenia pathology.   
Conclusions 
 In this study, we evaluated 667 miRNAs, 441 of which showed reliable expression in a 
postmortem brain sample consisting of SZ, BP and control subjects.  Twenty-two miRNAs were 
found to be differentially expressed between cases and controls, two of which, hsa-miR-7 and 
miR -212 were previously reported to be dysregulated in SZ.  To our knowledge, we were also 
the first to report differentially expressed miRNAs in BP disorder, and in agreement with 
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previous observations of a shared genetic etiology of SZ and BP20, we observed a large number 
of miRNAs with significant variance differences were shared by both disease groups.   
 This study also provides functional validation for two miRNAs implicated in 
schizophrenia by very different approaches, miR-132 via expression studies and miR-137 via a 
genetic study.  MiR-132 was shown to target NTF3, DISC1, and GRIK5 and mir-137 was shown 
to directly target CACNA1C, TCF4, and CDK6.  Our study provides additional evidence for 
miRNA involvement in the etiology of schizophrenia.  The nature of genes targeted by miR-132 
and miR-137 strongly supports dysfunction of neurotransmission (GRIK5, CACNA1C) and 
disruption of signaling pathways during development (NTF3, DISC1, TCF4, and CDK6), both of 
which strengthen previously existing hypotheses of schizophrenia etiology.  
Future Directions 
 Schizophrenia is a complex disease with many factors contributing to its etiology.  While 
it is likely that multiple pathways are involved in the pathogenesis of schizophrenia, the Wnt/β-
Catenin/GSK3β pathway appears to be a promising mechanism that may further elucidate the 
complexities of the disease.  Thus, future work could focus on dissecting the pathway further by 
assessing in detail, how the miR-132 or miR-137 affects members of the pathway individually, 
or more interestingly, collectively.  This can be accomplished by measuring gene expression for 
each member of the pathway after over-expression of the miRNAs  in vitro.  Given that miR-132 
and miR-137 target genes involved in neurotransmission and development, it would also be 
interesting to assess the effects of miR-132 and miR-137 in animal models.  This can be 
accomplished by over- or under-expression of the miRNA of interest in a mouse model and 
assessing the effects in specific brain regions of interest (DLPFC, STG) or more globally at 
different stages of development.               
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Appendix 1 
Graphical representation of descriptive measures of the SMRI sample. 
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Appendix 2 
Correlation plot of miRNA expression preamplified (WP) and not preamplified (NP). 
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Appendix 3 
Expression of endogenous controls.  Red (Top)=U6, Green (Middle)=RNU48 and Black 
(Bottom)=RNU44. 
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Appendix 4 
Detailed description of the median polish normalization approach. 
 Artifacts of measurement may systematically raise or lower all the miRNA values 
measured from one sample to another. If we observe that all samples are raised simultaneously, it 
is more likely that this reflects a systematic bias in the sample rather than the miRNAs actually 
being more abundant. Therefore, we attempted to compensate for such artifacts using the U6, 
U44, and U48 RNAs included as controls within the TLDA arrays on the common assumption 
that these RNAs are expressed at the same levels in all samples. However, we found that they 
were as variable across samples as many of the experimental miRNAs, thereby demonstrating 
that in our sample, the provided controls cannot be used for normalization. Thus, we adopted an 
alternate method used in medium sized microarray gene expression data sets to estimate a 
sample-specific compensation value.  
 First, we used the median polish procedure to estimate a centering constant using the 
most stably expressed genes. Median polish is a robust centering procedure, which is insensitive 
to a large number of truly differentially expressed miRNA genes. The procedure assumes that the 
majority of genes considered are unaffected by the conditions under study, and tries to fit 
centering constants for each sample. The idea is that differences in the medians of the samples 
reflect biases having to do with the sample preparation. The median polish algorithm iteratively 
subtracts medians of rows and columns until all rows and columns have a median of zero, while 
keeping track of the amounts subtracted from each row and column. In this case we worked 
iteratively: each of the two arrays (A and B) were processed separately; for array  for array A we 
pre-selected the 34 miRNA genes and for array B 26 miRNA genes with the smallest variance (< 
0.1) under the assumption that they were most likely to be stable. We then fit the median polish 
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Figure14: Correlations of the reference set 
of genes used for normalization across 
samples.  
to those genes only, and normalized the data by subtracting the sample means. We then 
determined the genes of smallest variance again and repeated the procedure until no change 
occurred.  
 Next, we tested post-hoc whether the assumptions of the normalizing procedure were 
valid. We were concerned that perhaps some 
genes were stable in the control subjects, but not 
in the case subjects. In fact, the within-diagnosis 
standard deviations of miRNA genes were 
highly correlated across the different groups 
(0.79 < r < 0.86, Figure 14). Furthermore, the 
correlations between samples of the set of 
reference genes used for normalization across 
samples was very high (mean correlation: 0.99; 
minimum pair-wise correlation: 0.96), confirming 
that these genes were indeed stably expressed in our samples. The normalization constants for 
each array were computed separately.  
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Appendix 5A 
Within plate correlation plots. 
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Appendix 5B 
Multi-dimensionality plot showing clustering of samples. 
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Appendix 6 
Statistics of normalized expression values for the 441 miRNAs. 
ID Count 
Aver. 
(Cq) SD CV % Range Skewness Kurtosis 
hsa-let-7a 87 18.92 0.43 2.30% 2.2701 0.3165 0.2851
hsa-let-7a* 87 28.14 0.77 2.73% 4.2356 0.8174 1.5093
hsa-let-7b 87 17.47 0.28 1.61% 1.3833 -0.9034 0.1916
hsa-let-7b* 87 27.03 0.78 2.87% 4.9655 4.2710 6.7163
hsa-let-7c 87 19.66 0.41 2.10% 2.4212 -5.2548 7.7019
hsa-let-7d 87 19.96 0.33 1.66% 2.044 5.8947 9.6632
hsa-let-7e 87 17.26 0.41 2.37% 2.2308 -1.1356 1.6802
hsa-let-7e* 87 29.06 0.56 1.93% 2.4563 1.2395 -1.0567
hsa-let-7f 87 21.49 0.50 2.33% 2.2821 -1.2064 -0.1848
hsa-let-7f-1* 87 28.40 0.80 2.82% 4.3268 -2.1882 2.6576
hsa-let-7f-2* 87 29.08 0.37 1.27% 2.0931 2.9943 2.4451
hsa-let-7g 87 20.28 0.33 1.63% 1.9367 3.6690 3.7113
hsa-let-7g* 87 28.27 1.61 5.71% 5.5744 1.6361 6.4364
hsa-let-7i* 87 29.48 0.63 2.13% 2.9014 0.0624 -0.4341
hsa-miR-1 87 26.68 0.68 2.57% 3.4263 3.3900 1.4303
hsa-miR-100 87 17.51 0.34 1.95% 1.4665 0.5593 -0.8982
hsa-miR-100* 87 30.57 0.82 2.67% 3.9843 2.6783 1.0260
hsa-miR-101 87 23.68 0.25 1.07% 1.5183 -0.3788 1.2102
hsa-miR-101* 87 29.72 0.88 2.97% 4.9734 -0.8521 0.6825
hsa-miR-103 87 20.18 0.21 1.04% 1.1272 -4.6704 5.0015
hsa-miR-105 87 27.17 0.53 1.96% 2.6583 -0.8954 -0.4686
hsa-miR-106a 87 20.26 0.42 2.05% 1.6684 -0.9735 -1.2973
hsa-miR-106b 87 21.75 0.32 1.48% 1.5013 -0.7111 -0.4000
hsa-miR-106b* 87 26.01 0.78 3.01% 5.3244 4.5852 6.5573
hsa-miR-107 87 23.86 0.44 1.86% 2.5924 -1.6183 2.0355
hsa-miR-10b* 87 29.68 1.02 3.44% 5.5488 -0.0950 1.6916
hsa-miR-122 87 26.85 2.06 7.69% 10.0607 -2.9378 0.4664
hsa-miR-124 87 20.81 0.38 1.81% 2.2141 1.5194 2.3255
hsa-miR-124* 87 25.59 0.53 2.06% 2.9863 2.1558 1.6603
hsa-miR-125a-3p 87 29.33 0.56 1.93% 2.9541 -1.8539 1.1719
hsa-miR-125a-5p 87 21.03 0.41 1.93% 1.9198 -1.3212 -0.8103
hsa-miR-125b 87 15.97 0.19 1.20% 1.0996 2.5733 2.7780
hsa-miR-125b-1* 87 27.45 0.63 2.28% 3.6651 -4.7028 5.0487
hsa-miR-125b-2* 87 24.49 0.35 1.43% 1.8304 -2.1258 2.6262
hsa-miR-126 87 17.60 0.39 2.20% 1.5321 0.3313 -1.8086
hsa-miR-126* 87 20.72 0.35 1.69% 1.4412 0.9034 -1.2456
hsa-miR-127-3p 87 19.17 0.34 1.80% 1.5058 0.3592 -0.8170
hsa-miR-127-5p 87 28.63 0.86 3.02% 3.8291 -1.7096 -0.8222
hsa-miR-128 87 18.73 0.38 2.05% 2.1199 2.0425 3.1106
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hsa-miR-129-3p 87 20.48 0.42 2.05% 2.1721 1.8457 1.0158
hsa-miR-129-5p 87 23.92 0.38 1.60% 2.071 0.1565 1.6737
hsa-miR-130a 87 23.12 0.38 1.63% 1.9778 2.2928 0.9944
hsa-miR-130b 87 24.65 0.40 1.61% 1.9943 -3.0882 1.8232
hsa-miR-130b* 87 26.53 0.41 1.53% 2.0706 -2.3041 0.6714
miR-132 87 17.47 0.47 2.69% 2.8203 2.8944 3.4303
miR-132* 87 27.18 0.68 2.49% 3.4555 0.3625 1.0389
hsa-miR-133a 87 23.13 0.40 1.72% 2.2208 0.4538 0.7701
hsa-miR-133b 87 24.98 0.38 1.50% 1.9497 -0.0391 -0.0757
hsa-miR-134 87 23.60 0.43 1.84% 2.337 -0.1243 0.1106
hsa-miR-135a 87 22.09 0.46 2.07% 2.6091 0.3674 1.4821
hsa-miR-135a* 87 21.14 0.54 2.55% 2.5556 -2.7362 0.2393
hsa-miR-135b 87 25.08 0.28 1.11% 1.3005 1.9241 0.2659
hsa-miR-136 87 31.89 0.79 2.47% 3.3366 -1.5626 -0.5988
hsa-miR-136* 87 23.82 0.31 1.30% 1.3905 -0.1032 -0.4930
hsa-miR-137 87 20.13 0.40 1.98% 2.0606 -0.3194 0.9275
hsa-miR-138 87 17.94 0.33 1.85% 2.7019 7.4656 22.2351
hsa-miR-138-1* 87 25.02 0.33 1.31% 2.0654 -3.2734 4.3541
hsa-miR-138-2* 87 24.15 0.46 1.88% 2.1638 0.2955 -0.7896
hsa-miR-139-3p 87 21.57 0.43 1.97% 2.6348 0.4056 2.2260
hsa-miR-139-5p 87 18.22 0.44 2.42% 1.9286 -0.8852 -1.0970
hsa-miR-140-3p 87 25.14 0.43 1.72% 2.2255 -0.7223 -0.3805
hsa-miR-140-5p 87 20.53 0.27 1.33% 1.2184 0.4208 -0.8578
hsa-miR-141 87 30.20 0.86 2.84% 4.1337 -2.6053 1.3481
hsa-miR-142-3p 87 22.00 0.52 2.37% 2.6063 -2.1093 1.0701
hsa-miR-142-5p 87 28.54 0.76 2.67% 4.0169 -0.6223 0.9147
hsa-miR-143 87 21.51 0.65 3.01% 3.4916 -4.5894 3.8018
hsa-miR-144* 87 25.02 0.84 3.36% 4.0201 1.0794 -0.6909
hsa-miR-145 87 17.83 0.64 3.57% 3.5266 -1.9825 1.3806
hsa-miR-145* 87 26.60 0.68 2.56% 3.4221 -2.0168 0.7136
hsa-miR-146a 87 21.51 0.35 1.63% 1.4798 -0.6886 -1.2820
hsa-miR-146b-3p 87 28.03 0.41 1.46% 2.0241 2.5881 1.1239
hsa-miR-146b-5p 87 20.74 0.38 1.81% 1.6842 0.3731 -0.7504
hsa-miR-148a 87 24.78 0.48 1.95% 2.5307 0.5218 0.4675
hsa-miR-148b 87 24.60 0.38 1.53% 2.0791 -2.5783 2.5591
hsa-miR-148b* 87 29.27 0.44 1.49% 2.7151 1.7787 3.3533
hsa-miR-149 87 18.34 0.44 2.42% 2.1824 0.7603 -0.2744
hsa-miR-150 87 21.05 0.40 1.89% 1.8247 0.4700 -0.3314
hsa-miR-151-3p 87 22.04 0.57 2.59% 2.8735 -0.6982 -0.0761
hsa-miR-152 87 23.14 0.33 1.43% 1.8354 -1.8806 1.2614
hsa-miR-153 87 26.98 0.62 2.30% 3.1414 0.5577 0.8549
hsa-miR-154 87 27.77 0.62 2.22% 3.2457 2.2368 1.8775
hsa-miR-154* 87 26.31 0.68 2.59% 3.614 3.0711 2.4678
hsa-miR-15a 87 22.88 1.36 5.95% 13.6252 15.5518 63.1890
hsa-miR-15a* 87 27.20 0.45 1.66% 2.2119 -1.2509 1.1206
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hsa-miR-15b 87 22.03 0.40 1.81% 2.3341 1.1943 1.4732
hsa-miR-16 87 19.47 0.50 2.57% 2.5271 -1.1617 0.2453
hsa-miR-16-1* 87 28.19 0.67 2.36% 3.1842 0.5733 0.4160
hsa-miR-17 87 20.07 0.41 2.04% 1.6213 0.2446 -1.4738
hsa-miR-17* 87 27.70 0.78 2.83% 4.121 1.0159 -0.6803
hsa-miR-181a 87 18.35 0.53 2.90% 2.9363 0.4191 0.5338
hsa-miR-181a* 87 23.91 0.44 1.86% 2.1818 -1.1201 0.0890
hsa-miR-181a-2* 87 24.91 0.38 1.54% 1.72 -1.5483 -0.4374
hsa-miR-181c 87 22.72 0.47 2.07% 2.5333 1.1857 0.6402
hsa-miR-181c* 87 23.25 0.32 1.39% 2.0113 0.9785 3.0822
hsa-miR-182 87 33.08 1.69 5.11% 7.6459 -2.8495 0.6042
hsa-miR-184 87 26.44 0.44 1.68% 2.1143 0.4286 -0.2667
hsa-miR-185 87 23.49 0.47 2.02% 2.0788 0.7608 -0.3664
hsa-miR-186 87 22.17 0.25 1.12% 1.2903 0.4069 0.1411
hsa-miR-187 87 25.92 0.80 3.10% 5.3938 -2.6110 5.7338
hsa-miR-188-5p 87 25.68 0.82 3.19% 4.2685 -2.3392 1.3768
hsa-miR-18a 87 24.77 0.48 1.96% 2.6443 -1.1691 1.4458
hsa-miR-18a* 87 29.50 0.76 2.59% 3.8157 -0.3771 0.0028
hsa-miR-18b 87 24.36 0.34 1.41% 2.3833 -4.7088 9.6091
hsa-miR-190 87 25.79 0.43 1.66% 1.8305 -0.5560 -0.9296
hsa-miR-190b 87 30.65 0.73 2.37% 3.5096 0.5310 -0.5975
hsa-miR-191 87 18.84 0.42 2.21% 1.6696 -0.9946 -1.1823
hsa-miR-192 87 25.68 0.48 1.86% 2.3049 -0.2541 0.1634
hsa-miR-192* 87 30.62 0.52 1.70% 3.2939 3.0681 5.3559
hsa-miR-193a-3p 87 30.12 1.21 4.01% 6.1 -1.1374 1.0431
hsa-miR-193a-5p 87 25.23 0.47 1.88% 2.3593 -1.6999 -0.0448
hsa-miR-193b 87 20.74 0.41 1.99% 1.9822 -0.4180 -0.4114
hsa-miR-193b* 87 25.96 0.55 2.13% 2.5074 -0.4129 -0.6098
hsa-miR-194 87 25.58 0.33 1.29% 1.4261 0.2985 -1.2154
hsa-miR-195 87 20.54 0.31 1.50% 1.6889 2.8017 1.4674
hsa-miR-197 87 20.91 0.47 2.25% 2.6035 -0.7538 1.3099
hsa-miR-199a-3p 87 23.99 0.63 2.62% 3.2026 -1.3596 0.0022
hsa-miR-199a-5p 87 28.55 0.95 3.34% 4.6276 0.1311 -0.5590
hsa-miR-199b-5p 87 28.82 0.71 2.46% 4.6123 0.1634 2.5528
hsa-miR-19a 87 22.22 0.50 2.26% 2.8502 -4.4479 6.1215
hsa-miR-19b 87 17.38 0.36 2.06% 1.8254 -1.9553 0.9810
hsa-miR-19b-1* 87 29.05 0.61 2.10% 3.3292 0.2485 0.2629
hsa-miR-200a 87 24.88 0.60 2.42% 2.7774 -0.4772 -0.6009
hsa-miR-200b 87 26.21 0.50 1.91% 2.5907 0.1336 0.1661
hsa-miR-200c 87 26.66 0.43 1.61% 2.5003 2.2497 2.4018
hsa-miR-202 87 29.03 1.38 4.76% 6.164 -0.7220 -1.0702
hsa-miR-203 87 23.31 0.39 1.66% 1.9311 0.8256 -0.3526
hsa-miR-204 87 20.10 0.31 1.54% 1.5067 0.0860 0.0748
hsa-miR-205 87 32.02 1.23 3.86% 6.7576 2.3491 1.2164
hsa-miR-206 87 31.20 0.73 2.33% 4.1648 2.4354 1.6443
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hsa-miR-20a 87 20.03 0.42 2.10% 2.4962 -0.4270 1.2913
hsa-miR-20a* 87 26.92 0.59 2.18% 2.8892 1.4192 0.3082
hsa-miR-20b 87 22.73 0.33 1.43% 1.7347 -1.8776 0.0482
hsa-miR-20b* 87 32.09 1.60 4.98% 8.9037 -0.3853 2.1889
hsa-miR-21 87 19.99 0.50 2.48% 2.6267 0.3443 0.5302
hsa-miR-21* 87 29.21 0.99 3.39% 4.4701 -0.2039 -0.5986
hsa-miR-210 87 22.20 0.46 2.07% 2.2139 -1.1587 -0.1885
hsa-miR-212 87 23.04 0.54 2.36% 3.1163 2.0453 2.2044
hsa-miR-214 87 24.44 0.67 2.74% 3.368 -1.2799 0.0650
hsa-miR-214* 87 28.35 0.80 2.81% 3.8914 -1.4320 -0.1119
hsa-miR-215 87 25.70 0.39 1.52% 2.2111 -2.9435 4.9399
hsa-miR-216b 87 29.65 1.13 3.80% 5.6674 1.1889 0.2556
hsa-miR-217 87 31.34 1.23 3.94% 6.8314 1.6268 1.4686
hsa-miR-218 87 18.22 0.38 2.08% 2.4744 0.9099 3.2209
hsa-miR-218-2* 87 29.90 0.56 1.87% 2.422 -0.0017 -1.1275
hsa-miR-219-2-3p 87 21.06 0.87 4.13% 4.3646 1.5532 0.3272
hsa-miR-219-5p 87 20.11 0.93 4.61% 4.4281 1.3551 -0.0507
hsa-miR-22 87 21.44 0.55 2.58% 3.7524 -0.0796 4.2355
hsa-miR-22* 87 23.19 0.52 2.23% 2.453 2.2130 -0.3719
hsa-miR-221 87 19.39 0.35 1.80% 1.7726 1.4205 0.7313
hsa-miR-221* 87 28.93 0.49 1.68% 2.5785 3.8111 3.0580
hsa-miR-222 87 18.46 0.40 2.15% 2.219 2.4654 2.7550
hsa-miR-222* 87 25.87 0.88 3.40% 4.3797 0.4590 0.0180
hsa-miR-223 87 19.60 0.49 2.48% 2.6463 -2.6955 2.1490
hsa-miR-223* 87 28.92 0.78 2.70% 3.2223 -0.7672 -1.1056
hsa-miR-224 87 28.39 0.76 2.67% 3.6252 -0.9306 -0.2840
hsa-miR-23b 87 22.06 0.50 2.25% 2.7013 0.5501 0.6236
hsa-miR-24 87 17.11 0.25 1.47% 1.2732 0.0286 0.1246
hsa-miR-25 87 23.50 0.36 1.54% 1.8257 -0.7096 0.6084
hsa-miR-26a 87 17.94 0.25 1.42% 1.4163 2.8493 2.2414
hsa-miR-26a-1* 87 28.20 0.57 2.02% 2.481 -0.5544 -0.8955
hsa-miR-26a-2* 87 29.15 0.97 3.33% 5.6657 -3.3561 3.1734
hsa-miR-26b 87 21.00 0.37 1.75% 2.7542 -1.3667 6.4597
hsa-miR-26b* 87 27.79 0.34 1.23% 1.721 -1.7352 1.0943
hsa-miR-27a 87 23.05 0.35 1.53% 1.7225 -0.7769 0.4044
hsa-miR-27a* 87 29.43 0.83 2.83% 4.9145 -0.7297 1.2658
hsa-miR-27b 87 21.37 0.37 1.74% 2.1213 0.7003 1.5250
hsa-miR-27b* 87 25.84 0.45 1.76% 2.2952 0.7933 -0.3419
hsa-miR-28-3p 87 23.09 0.45 1.93% 3.4311 8.1041 23.3063
hsa-miR-28-5p 87 23.51 0.22 0.92% 1.0848 -0.6670 -0.0598
hsa-miR-296-5p 87 23.67 0.43 1.81% 1.9928 0.0409 -0.7087
hsa-miR-299-5p 87 27.46 0.61 2.23% 3.204 3.7068 2.1575
hsa-miR-29a 87 17.64 0.23 1.32% 1.0223 -0.3084 -0.6439
hsa-miR-29a* 87 24.91 0.39 1.55% 2.1759 4.1430 4.6904
hsa-miR-29b 87 21.30 0.39 1.82% 2.2267 1.1587 1.3419
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hsa-miR-29b-2* 87 26.23 0.30 1.15% 1.8765 5.8686 9.4044
hsa-miR-29c 87 20.10 0.25 1.23% 1.5466 1.8456 2.3149
hsa-miR-29c* 87 23.71 0.27 1.13% 1.5767 5.0536 5.2358
hsa-miR-301a 87 21.49 0.32 1.51% 1.564 -0.3127 -0.3375
hsa-miR-301b 87 27.78 0.37 1.33% 2.1808 0.5409 2.7999
hsa-miR-302a 87 31.54 1.39 4.41% 8.904 -2.4991 4.6879
hsa-miR-302a* 87 32.52 1.47 4.52% 7.837 -0.7376 2.5463
hsa-miR-302b 87 31.14 0.59 1.89% 2.9762 0.8044 0.5420
hsa-miR-302c 87 31.76 1.91 6.02% 8.5246 -2.6295 -0.1135
hsa-miR-30a 87 20.45 0.28 1.36% 1.3192 0.2114 -1.1273
hsa-miR-30a* 87 20.24 0.21 1.04% 1.2331 -2.6300 3.4824
hsa-miR-30b 87 17.22 0.37 2.17% 2.0399 2.4390 1.2340
hsa-miR-30c 87 16.81 0.30 1.76% 1.4857 0.1236 -0.0915
hsa-miR-30c-1* 87 27.37 0.55 2.02% 3.3174 3.7290 4.0428
hsa-miR-30d 87 21.92 0.38 1.75% 2.3889 -3.3431 6.0141
hsa-miR-30d* 87 25.71 0.30 1.15% 1.5849 1.6164 0.7561
hsa-miR-30e 87 21.87 0.20 0.90% 0.8044 -0.8268 -1.7647
hsa-miR-30e* 87 20.02 0.20 0.98% 1.1254 -0.9048 1.2045
hsa-miR-31 87 21.50 0.30 1.41% 1.6755 -2.2301 1.5875
hsa-miR-32 87 29.18 0.84 2.89% 4.8023 2.4062 2.7324
hsa-miR-320 87 21.74 0.59 2.70% 2.8032 -0.9462 -0.2666
hsa-miR-323-3p 87 22.40 0.36 1.60% 1.6264 2.3320 -0.3355
hsa-miR-324-3p 87 23.74 0.22 0.94% 1.0742 -0.9625 -0.4302
hsa-miR-324-5p 87 21.48 0.37 1.72% 1.6916 1.8813 -0.3928
hsa-miR-326 87 28.04 0.48 1.72% 2.4658 -0.1472 -0.0142
hsa-miR-328 87 18.52 0.29 1.59% 1.7475 4.5034 5.6440
hsa-miR-329 87 26.31 0.38 1.46% 1.8993 1.3412 0.2967
hsa-miR-330-3p 87 21.63 0.40 1.84% 1.8271 -0.8022 -0.6214
hsa-miR-330-5p 87 26.77 0.53 1.96% 2.4719 -0.6744 -1.0527
hsa-miR-331-3p 87 18.67 0.30 1.62% 1.8819 2.6233 2.7904
hsa-miR-331-5p 87 27.88 0.46 1.64% 2.5806 -0.1008 1.2568
hsa-miR-335 87 21.80 0.32 1.46% 1.6007 0.9162 0.5616
hsa-miR-335* 87 25.00 0.42 1.68% 2.0397 -2.0724 0.0676
hsa-miR-337-3p 87 26.68 0.76 2.83% 5.0823 0.2471 4.2107
hsa-miR-337-5p 87 29.39 1.32 4.49% 6.9669 4.1160 2.8735
hsa-miR-338-3p 87 23.79 0.83 3.48% 4.0882 -0.7053 -0.1190
hsa-miR-339-3p 87 23.81 0.34 1.41% 2.1237 1.0283 3.1958
hsa-miR-339-5p 87 23.91 0.40 1.69% 1.9126 -1.7554 0.0145
hsa-miR-33a* 87 27.20 0.45 1.64% 2.2603 -2.5612 1.6085
hsa-miR-340 87 21.90 0.46 2.08% 2.0941 0.6383 -0.3370
hsa-miR-340* 87 22.98 0.49 2.12% 2.1664 0.9281 -0.2301
hsa-miR-342-3p 87 18.08 0.36 1.98% 1.5964 -0.8807 -1.4193
hsa-miR-342-5p 87 25.89 0.44 1.70% 2.0357 -0.9114 -0.9061
hsa-miR-345 87 23.69 0.35 1.49% 1.5454 0.1758 -0.8081
hsa-miR-34a 87 21.82 0.38 1.75% 1.6124 1.7313 -0.5488
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hsa-miR-34a* 87 26.12 0.35 1.33% 1.6497 0.6446 -0.5474
hsa-miR-34b* 87 27.22 0.81 2.97% 3.5598 1.1079 -0.9286
hsa-miR-34c-5p 87 25.70 0.74 2.89% 3.8366 0.6646 -0.0173
hsa-miR-361-3p 87 23.82 0.55 2.32% 3.5974 3.9507 7.6584
hsa-miR-361-5p 87 23.83 0.26 1.08% 1.5285 1.0531 2.3510
hsa-miR-362-3p 87 28.09 0.49 1.76% 2.614 2.6006 2.1986
hsa-miR-362-5p 87 26.79 0.31 1.17% 1.673 0.3343 0.3478
hsa-miR-363 87 26.34 0.32 1.20% 1.7829 0.6989 0.5843
hsa-miR-365 87 21.03 0.35 1.68% 1.6758 1.8187 -0.0811
hsa-miR-367 87 31.36 1.88 5.98% 11.1117 -0.8832 4.6070
hsa-miR-369-3p 87 29.04 0.70 2.42% 3.538 1.4679 0.5272
hsa-miR-369-5p 87 29.15 0.53 1.83% 2.695 1.6734 0.6065
hsa-miR-370 87 21.73 0.37 1.71% 1.8575 -0.1173 0.8297
hsa-miR-372 87 32.02 2.67 8.34% 12.688 -0.7476 -0.4479
hsa-miR-374a 87 21.80 0.43 1.96% 2.6492 1.0093 2.6856
hsa-miR-374a* 87 29.79 0.82 2.75% 5.626 6.8915 13.1055
hsa-miR-374b 87 21.60 0.45 2.07% 2.5281 3.0915 3.2646
hsa-miR-374b* 87 30.05 0.86 2.85% 5.2577 -4.6488 8.0278
hsa-miR-375 87 25.52 0.47 1.84% 2.9372 0.0246 1.7234
hsa-miR-376a 87 23.31 0.32 1.38% 1.6576 -0.0150 0.2917
hsa-miR-376a* 87 27.95 0.49 1.75% 2.396 2.3781 0.2769
hsa-miR-376c 87 22.59 0.26 1.14% 1.1947 -0.8527 -0.8033
hsa-miR-377 87 28.59 0.76 2.65% 4.342 1.9429 2.5011
hsa-miR-377* 87 27.68 0.50 1.81% 2.3278 0.6377 -0.5355
hsa-miR-378 87 25.98 0.38 1.48% 2.445 -1.9289 4.7760
hsa-miR-378* 87 30.03 0.41 1.38% 2.1715 -0.4978 5.2227
hsa-miR-379 87 22.62 0.41 1.82% 2.2375 0.5529 2.1352
hsa-miR-379* 87 28.65 0.62 2.17% 2.7437 -1.7587 -0.5575
hsa-miR-380 87 28.14 0.94 3.35% 4.2823 -1.8834 -0.0722
hsa-miR-380* 87 27.15 0.41 1.50% 1.9358 -0.3484 -0.9582
hsa-miR-381 87 29.13 0.54 1.84% 2.9734 0.7438 0.8320
hsa-miR-382 87 20.52 0.35 1.71% 1.8909 0.6971 0.8369
hsa-miR-383 87 21.68 0.39 1.81% 2.7751 3.6631 8.3822
hsa-miR-409-3p 87 22.03 0.51 2.30% 3.0612 -0.1851 1.7361
hsa-miR-409-5p 87 26.09 0.52 2.01% 2.5125 0.8050 -0.4895
hsa-miR-410 87 23.49 0.38 1.62% 2.1602 2.0876 2.1263
hsa-miR-411 87 22.78 0.38 1.65% 1.6122 -0.5449 -1.0115
hsa-miR-411* 87 26.99 0.40 1.50% 1.9328 -0.1164 -0.6901
hsa-miR-422a 87 29.94 0.52 1.75% 2.3978 1.0532 -0.2209
hsa-miR-423-5p 87 24.12 0.55 2.30% 2.8542 -0.8682 1.2729
hsa-miR-424 87 28.64 0.59 2.05% 2.9741 0.5664 -0.5622
hsa-miR-424* 87 25.48 0.69 2.71% 4.9076 1.0410 6.9127
hsa-miR-425 87 22.23 0.28 1.25% 1.2846 0.4850 -0.3057
hsa-miR-425* 87 25.98 0.34 1.30% 2.3555 -2.9515 7.7714
hsa-miR-429 87 30.03 0.59 1.98% 2.7815 1.1113 -0.3374
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hsa-miR-431 87 26.98 1.11 4.12% 5.4307 1.5201 0.2728
hsa-miR-431* 87 26.86 1.19 4.44% 6.7544 -0.8758 0.0231
hsa-miR-432 87 23.70 0.41 1.72% 3.0775 -7.5521 20.1181
hsa-miR-433 87 22.68 0.35 1.55% 2.3559 1.0733 4.3338
hsa-miR-448 87 29.32 1.16 3.96% 5.658 -2.3581 0.9789
hsa-miR-449a 87 31.37 1.60 5.10% 8.208 -1.8597 0.9920
hsa-miR-449b 87 30.61 1.22 4.00% 7.1756 -1.7078 7.3111
hsa-miR-450a 87 29.26 0.69 2.37% 3.0832 -0.0142 -0.8315
hsa-miR-451 87 21.04 0.74 3.52% 4.1163 -0.5332 0.7486
hsa-miR-452 87 28.69 0.68 2.36% 3.8547 -0.8035 0.7374
hsa-miR-454 87 23.61 0.52 2.20% 2.1746 -1.2750 -1.1289
hsa-miR-454* 87 30.53 1.04 3.39% 6.582 2.5848 4.4825
hsa-miR-455-3p 87 25.40 0.54 2.13% 2.5456 -0.3328 -0.1728
hsa-miR-455-5p 87 26.47 0.40 1.50% 2.3705 -1.2120 2.2594
hsa-miR-483-5p 87 26.66 0.81 3.04% 3.6908 -0.2070 -0.3372
hsa-miR-484 87 19.75 0.35 1.77% 1.5947 -1.8024 -0.1831
hsa-miR-485-3p 87 23.30 0.45 1.91% 2.1891 2.7476 1.1189
hsa-miR-485-5p 87 22.42 0.88 3.91% 3.9679 -3.0570 0.4264
hsa-miR-486-3p 87 26.96 0.63 2.35% 3.5735 0.4927 2.1370
hsa-miR-486-5p 87 26.57 0.63 2.36% 3.2597 -0.2521 0.2950
hsa-miR-487a 87 26.61 0.40 1.49% 1.9389 0.4778 -0.0337
hsa-miR-487b 87 22.80 0.48 2.10% 2.5878 3.0554 2.4604
hsa-miR-488 87 24.69 0.36 1.45% 1.7402 -1.0800 -0.0846
hsa-miR-488* 87 26.83 0.83 3.09% 3.7127 2.7080 -0.1266
hsa-miR-489 87 28.07 0.92 3.29% 4.1609 -1.1035 -1.2450
hsa-miR-490-3p 87 26.82 0.60 2.23% 3.2608 -2.2773 2.4126
hsa-miR-491-5p 87 22.26 0.35 1.56% 1.9118 0.5318 0.4121
hsa-miR-493 87 30.49 1.24 4.08% 5.7348 -2.9167 0.6796
hsa-miR-493* 87 30.48 0.93 3.07% 4.6776 1.5547 0.6912
hsa-miR-494 87 25.53 0.36 1.40% 1.7777 -0.3752 0.4274
hsa-miR-495 87 21.34 0.41 1.92% 2.2878 2.5685 2.2310
hsa-miR-496 87 29.91 1.07 3.59% 6.2374 -2.0529 2.5059
hsa-miR-497 87 23.67 0.60 2.52% 3.508 -3.0352 3.8653
hsa-miR-499-5p 87 27.67 0.87 3.16% 4.6997 0.7810 0.7380
hsa-miR-500 87 27.16 0.38 1.39% 2.0771 -0.2873 0.4962
hsa-miR-501-5p 87 24.79 0.31 1.27% 1.6653 -1.0309 1.2514
hsa-miR-502-3p 87 28.03 0.38 1.34% 1.7678 1.2950 -0.0579
hsa-miR-502-5p 87 28.90 0.59 2.04% 2.7383 -1.9555 -0.0074
hsa-miR-503 87 28.18 0.86 3.05% 4.0705 -1.3751 -0.3175
hsa-miR-504 87 23.96 0.58 2.42% 2.4887 2.6098 -0.5576
hsa-miR-505 87 26.38 0.50 1.90% 2.1368 0.5987 -1.0277
hsa-miR-505* 87 26.70 0.56 2.10% 3.8466 1.9410 6.1812
hsa-miR-508-3p 87 30.27 1.45 4.81% 7.8562 4.8488 4.9598
hsa-miR-509-3p 87 27.49 0.52 1.88% 2.605 -0.4186 0.9210
hsa-miR-509-5p 87 27.67 0.54 1.94% 3.708 1.7619 6.0914
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hsa-miR-511 87 30.14 0.90 2.98% 4.7662 1.7273 1.0922
hsa-miR-512-3p 87 30.02 1.06 3.54% 6.3551 1.0541 1.5855
hsa-miR-513-3p 87 29.04 0.98 3.39% 4.6866 -1.0150 -0.4232
hsa-miR-516a-3p 87 30.06 1.14 3.80% 5.7425 -1.7989 1.6966
hsa-miR-517a 87 28.23 0.84 2.97% 3.6765 0.6927 -1.0419
hsa-miR-517b 87 28.71 1.04 3.62% 4.8816 -0.0299 0.9497
hsa-miR-517c 87 28.05 0.71 2.52% 3.3924 1.7502 -0.0193
hsa-miR-518a-3p 87 30.51 1.16 3.80% 5.362 1.3533 0.7106
hsa-miR-518e 87 28.64 1.03 3.61% 5.7106 2.1742 2.3470
hsa-miR-518f 87 29.80 0.70 2.36% 3.1773 -2.4861 -0.1581
hsa-miR-519a 87 26.71 0.55 2.07% 3.6663 1.7505 2.8420
hsa-miR-519b-3p 87 29.99 0.97 3.25% 4.4808 -1.5938 -0.1082
hsa-miR-519d 87 30.04 1.34 4.45% 5.8157 -0.7343 -0.3909
hsa-miR-520c-3p 87 30.11 0.68 2.27% 3.7471 1.5296 0.9317
hsa-miR-522 87 28.20 0.79 2.78% 4.6921 1.1684 1.4871
hsa-miR-524-3p 87 27.91 0.60 2.15% 5.1625 12.5474 40.6848
hsa-miR-526b* 87 30.60 0.70 2.30% 3.7135 -0.5236 0.1711
hsa-miR-532-3p 87 24.37 0.23 0.93% 1.0835 0.0234 -0.5910
hsa-miR-532-5p 87 23.28 0.26 1.10% 1.3187 0.6427 0.6372
hsa-miR-539 87 22.08 0.39 1.78% 1.9667 -0.0754 0.2753
hsa-miR-541 87 28.08 1.02 3.62% 4.9179 -1.1218 0.0268
hsa-miR-542-3p 87 30.62 0.52 1.71% 2.4926 0.0285 0.1091
hsa-miR-542-5p 87 30.81 1.14 3.69% 5.7075 -0.6490 0.2851
hsa-miR-543 87 23.86 0.50 2.08% 2.3508 1.9931 0.2583
hsa-miR-544 87 31.35 1.07 3.43% 6.3722 -3.3555 5.3541
hsa-miR-545 87 28.59 0.63 2.22% 3.3303 0.4377 1.3515
hsa-miR-545* 87 31.07 0.93 2.99% 5.5556 -7.1073 13.1239
hsa-miR-548a-3p 87 32.59 1.33 4.08% 6.2029 -1.0821 0.2675
hsa-miR-548b-5p 87 30.20 1.24 4.11% 7.2319 -1.1296 1.8294
hsa-miR-548c-5p 87 31.15 1.32 4.22% 6.8768 0.2268 -0.0129
hsa-miR-548d-5p 87 30.13 1.06 3.51% 5.4862 -0.7121 -0.2316
hsa-miR-550 87 31.66 1.12 3.55% 5.2627 -0.6288 -0.3162
hsa-miR-550* 87 29.83 0.74 2.49% 3.494 -0.9458 -0.6337
hsa-miR-551b 87 27.93 0.45 1.62% 2.3743 -0.0355 0.0301
hsa-miR-551b* 87 29.62 0.83 2.82% 3.8727 -0.2279 -0.2755
hsa-miR-564 87 26.45 0.72 2.70% 3.4256 -1.1561 0.2090
hsa-miR-565 87 22.88 1.09 4.74% 5.5068 0.3885 0.6631
hsa-miR-570 87 31.15 1.09 3.51% 5.7753 -0.1848 0.9763
hsa-miR-572 87 29.01 0.86 2.97% 3.567 -1.5916 -0.6171
hsa-miR-573 87 29.03 0.93 3.21% 7.4359 1.1158 12.3170
hsa-miR-574-3p 87 20.91 0.65 3.12% 3.3896 -0.1285 -0.2373
hsa-miR-576-3p 87 29.99 0.45 1.52% 2.0575 -1.0686 -0.3983
hsa-miR-579 87 28.48 0.63 2.21% 3.0134 0.3992 -0.3416
hsa-miR-580 87 29.49 0.94 3.19% 5.2454 3.6888 3.5561
hsa-miR-582-3p 87 28.59 0.37 1.30% 1.9653 0.7083 0.8826
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hsa-miR-582-5p 87 28.41 0.63 2.23% 2.7351 -1.5011 -0.4987
hsa-miR-584 87 24.65 1.02 4.13% 4.4694 0.8097 -1.0850
hsa-miR-589 87 29.76 0.62 2.08% 3.1784 0.8055 -0.4932
hsa-miR-589* 87 27.98 0.67 2.39% 3.6559 1.5268 0.8245
hsa-miR-590-5p 87 24.42 0.40 1.62% 2.0464 -1.4565 0.6058
hsa-miR-592 87 24.31 0.37 1.52% 1.9225 0.8407 0.4653
hsa-miR-597 87 26.11 0.40 1.54% 1.8074 0.6500 -1.4843
hsa-miR-598 87 22.00 0.34 1.54% 1.7238 3.4567 2.1315
hsa-miR-601 87 30.36 0.72 2.36% 3.7416 -0.8191 0.4323
hsa-miR-604 87 28.40 0.76 2.66% 5.5177 2.3643 9.4831
hsa-miR-610 87 27.45 0.93 3.40% 5.1605 1.4030 0.9475
hsa-miR-616* 87 28.83 0.63 2.19% 3.1673 -0.2763 -0.1598
hsa-miR-618 87 30.45 0.94 3.08% 6.0126 3.8193 5.1702
hsa-miR-624- 87 31.00 1.48 4.77% 8.6436 0.1277 1.8373
hsa-miR-625 87 25.30 0.68 2.70% 3.3277 0.1514 -0.6302
hsa-miR-625* 87 23.24 0.75 3.25% 4.0064 -0.0426 0.2926
hsa-miR-627 87 33.06 1.42 4.30% 7.1381 -2.7823 2.4342
hsa-miR-628-3p 87 25.44 0.49 1.94% 3.1666 -3.6135 4.6869
hsa-miR-628-5p 87 24.03 0.49 2.02% 2.4341 1.1174 0.7197
hsa-miR-629 87 30.04 0.58 1.92% 3.6583 1.8484 3.1220
hsa-miR-629* 87 28.82 0.69 2.38% 4.723 1.2463 3.8706
hsa-miR-630 87 27.74 0.57 2.05% 4.2825 -3.6295 9.6709
hsa-miR-632 87 28.43 0.67 2.35% 3.118 -2.6293 0.7284
hsa-miR-635 87 31.21 1.70 5.44% 7.7309 0.2793 -0.3055
hsa-miR-636 87 29.19 0.73 2.50% 3.6721 -2.5270 0.5664
hsa-miR-638 87 26.85 0.69 2.59% 4.4294 2.7810 3.4085
hsa-miR-639 87 27.43 0.81 2.95% 4.0131 -0.2351 0.2687
hsa-miR-641 87 28.11 0.66 2.33% 3.7886 -0.0863 1.6593
hsa-miR-642 87 25.29 0.85 3.34% 4.5925 3.3106 2.6008
hsa-miR-645 87 32.09 0.84 2.62% 6.2224 5.2804 12.9137
hsa-miR-651 87 31.43 0.97 3.08% 4.1627 1.5053 -0.2930
hsa-miR-652 87 23.69 0.38 1.62% 2.0338 0.9632 0.6927
hsa-miR-654-3p 87 29.85 0.61 2.04% 3.2812 1.0596 1.2859
hsa-miR-654-5p 87 26.08 0.68 2.61% 3.2108 -0.1440 -0.5892
hsa-miR-655 87 24.54 0.50 2.05% 2.3343 2.2047 -0.2257
hsa-miR-656 87 24.48 0.55 2.24% 2.4772 1.5192 -0.7547
hsa-miR-659 87 25.21 0.64 2.53% 3.2628 -1.1106 -0.3333
hsa-miR-660 87 23.40 0.22 0.93% 1.3372 0.1890 1.8780
hsa-miR-661 87 23.59 1.25 5.30% 5.9389 -0.9593 0.1131
hsa-miR-668 87 24.50 0.83 3.38% 4.5818 0.9264 1.3165
hsa-miR-671-3p 87 26.47 0.40 1.52% 1.9815 -1.1972 -0.5689
hsa-miR-7 87 23.10 0.50 2.17% 2.4649 1.2294 1.0397
hsa-miR-708 87 22.06 0.31 1.40% 1.6134 2.4587 1.9682
hsa-miR-7-1* 87 21.61 0.55 2.52% 2.5382 -0.3521 -0.7111
hsa-miR-7-2* 87 25.45 0.48 1.87% 2.2976 0.0963 -0.0039
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hsa-miR-744 87 21.45 0.29 1.33% 1.2281 0.6223 -1.2352
hsa-miR-744* 87 25.19 0.26 1.04% 1.3522 2.3531 0.6751
hsa-miR-758 87 25.86 0.48 1.85% 2.5211 -0.7824 0.5814
hsa-miR-760 87 24.43 0.40 1.65% 2.0608 -3.4882 1.4101
hsa-miR-766 87 22.01 0.40 1.80% 2.2126 -0.1552 0.5090
hsa-miR-767-5p 87 26.87 0.41 1.51% 2.103 -2.2150 0.9308
hsa-miR-768-3p 87 19.99 0.45 2.25% 2.4696 -0.7559 1.0098
hsa-miR-769-3p 87 26.96 0.60 2.21% 2.7319 -0.0659 -0.7050
hsa-miR-769-5p 87 20.94 0.26 1.24% 1.4223 -3.1445 2.4059
hsa-miR-770-5p 87 24.41 0.47 1.94% 3.869 -10.6307 32.7795
hsa-miR-801 87 20.33 1.13 5.56% 5.0423 -0.8084 -0.7472
hsa-miR-873 87 28.28 0.57 2.03% 2.8843 -1.1280 0.3823
hsa-miR-874 87 21.90 0.47 2.14% 2.211 -0.4616 -0.3955
hsa-miR-875-5p 87 28.89 0.85 2.95% 7.2964 12.3539 39.0033
hsa-miR-876-3p 87 28.74 0.48 1.67% 2.8366 0.2205 1.9367
hsa-miR-876-5p 87 27.11 0.53 1.94% 2.7332 0.9714 0.3346
hsa-miR-877 87 25.67 0.39 1.50% 2.1519 -2.1742 2.3473
hsa-miR-885-5p 87 19.37 0.42 2.17% 2.0051 3.0987 1.1379
hsa-miR-886-3p 87 22.34 0.97 4.35% 5.1487 -1.1772 0.3410
hsa-miR-886-5p 87 24.22 1.19 4.91% 7.9606 -1.5284 3.4195
hsa-miR-888 87 31.57 0.94 2.97% 6.2342 -0.7815 3.4130
hsa-miR-889 87 24.83 0.49 1.97% 2.3482 0.2971 -0.0462
hsa-miR-891a 87 29.08 0.93 3.22% 4.4933 -1.2085 -0.3989
hsa-miR-9 87 14.24 0.33 2.30% 1.7025 0.3642 0.4329
hsa-miR-9* 87 17.32 0.36 2.07% 1.754 2.9107 1.2067
hsa-miR-922 87 30.26 1.31 4.33% 5.8424 -0.6403 -0.7653
hsa-miR-923 87 18.00 1.68 9.31% 9.6587 0.3224 1.6096
hsa-miR-92a 87 21.25 0.54 2.55% 2.9362 2.6723 1.1264
hsa-miR-92a-1* 87 29.63 1.30 4.40% 6.0496 0.7230 -0.8081
hsa-miR-93 87 21.97 0.78 3.55% 4.3472 -11.3817 18.9680
hsa-miR-93* 87 27.48 0.48 1.74% 3.0131 -3.6741 5.1601
hsa-miR-935 87 21.31 0.56 2.62% 2.5439 0.5209 -0.5144
hsa-miR-941 87 26.44 0.75 2.85% 3.7278 -0.3129 -0.4427
hsa-miR-942 87 29.62 0.67 2.26% 2.8587 -0.5127 -0.8253
hsa-miR-944 87 30.33 0.65 2.14% 5.8944 10.4312 35.9124
hsa-miR-95 87 21.28 0.34 1.59% 1.7749 -0.3805 -0.2620
hsa-miR-96 87 30.98 1.30 4.21% 6.366 -0.7816 0.2530
hsa-miR-98 87 20.94 0.55 2.63% 3.1522 -6.5607 7.9800
hsa-miR-99a 87 17.27 0.34 1.98% 1.7092 -0.7251 -0.4236
hsa-miR-99a* 87 25.43 0.21 0.83% 1.0857 -0.4597 0.2091
hsa-miR-99b 87 18.83 0.25 1.32% 1.1188 0.0502 -0.9098
hsa-miR-99b* 87 27.45 0.64 2.32% 5.4086 -2.8980 19.7534
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Figure15. Normal quantile plots of t-scores from seven major covariates tested in the SMRI 
postmortem brains. The diagonal line traces random distribution potential technical covariates.  
 
Appendix 7 
Inclusion of demographic covariates in the SMRI sample. 
 
In addition to disease status, SMRI provides information of potential confounding variables, 
which should be investigated carefully and, if necessary, included as covariates in subsequent 
analyses. The measures of miRNA abundance could be affected by a variety of factors, 
including: gender, age, post-mortem interval (PMI), refrigerator interval (RI), pH, RIN, drug use, 
alcohol use, anti-psychotic use, and duration of disease.  
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Figure 16: Normal quantile plots of t-scores from 
RIN measures tested in all three diagnostic 
groups of the SMRI postmortem brains. The 
diagonal line traces the normal distribution of 
expected values.  
 Ideally we would want to estimate each covariate’s effect on each miRNA. However, 
with approximately 30 cases per condition, following the usual “statistician’s rule-of-thumb” to 
estimate N parameters would require O(N) cases.  Thus, in this specific sample we would be able 
to estimate only five of these parameters for each miRNA.  Therefore, we tested for the effect of 
each covariate by itself within each diagnostic group separately in order to reduce the number of 
parameters in each fit.  We then computed t-statistics for these effects. To our surprise, for 
almost all covariates the estimated effects were 
indistinguishable from random noise, as shown 
in Figure 15.  We found no significant effects 
for age (not shown) or sex, and only few effects 
significant for pH, but since sex and pH are 
commonly used as covariates, these factors 
were explicitly fitted as such in the linear 
model together with diagnosis.  Cumulative anti-
psychotic use gave the most significant 
observation, which is discussed further below.  We 
also estimated the coefficients of the effects within each group separately and then compared 
these estimates across groups.  Generally, we found that estimates from different diagnostic 
groups were only very weakly correlated, supporting the idea that the corresponding factors had 
no systematic effect on miRNA abundance measures.  The correlations between coefficients for 
the seven covariates estimated separately in BPD and SZ are shown in Figures 15 and 16. The 
highest correlations were 0.24 for pH estimated in BPD and control samples separately, and 0.20 
for anti-psychotic use estimated within BPD and SZ separately.  
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Figure 17: Correspondence between estimates of covariate effects in 
BPD (y-axis) and SZ (x-axis). 
 One drawback of the SMRI sample is the provided measurement of neuroleptics, which is 
given in fluphenazine equivalents. Because this measurement does not distinguish specific 
individual antipsychotic drug treatments, its effects on gene expression cannot be parsed out and 
hence cannot be measured 
separately.  As different 
antipsychotic drugs are likely to 
have different, if not opposing 
effects on gene expression, we 
cannot provide an estimate of the 
individual drug effects on miRNA 
expression.  Regardless, the effect 
of anti-psychotic use would be 
most crucial in the comparison of 
SZ and control groups.  We first 
noted that the effect size 
estimated for SZ was little 
correlated with that estimated for BPD, and second the effect size was also much smaller within 
the SZ group (Figure 17, top left).  Therefore, since the best estimate of the effect seemed to be 
so small, we decided not to use anti-psychotic use as a covariate because it would be completely 
confounded with the effect (disease) we were trying to estimate. 
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Appendix 8 
miRNAs with significant variances in SZ and BP groups compared to controls.  miRNAs in bold 
overlap in both disease groups. 
BP miRNAs P-value  Q-value SCH miRNAs P-value Q-value 
hsa-miR-98 1.05E-18 4.73E-16 hsa-miR-875-5p 1.67E-06 0.00075334 
hsa-miR-218 1.04E-07 2.34E-05 hsa-miR-361-5p 1.78E-06 0.000401188
hsa-miR-299-5p 7.44E-07 0.000111644 hsa-miR-99b 1.05E-05 0.001184639
hsa-miR-129-3p 1.81E-06 0.000204075 hsa-miR-29b-2 1.53E-05 0.001381018
hsa-miR-138 2.47E-06 0.000222135 hsa-miR-432 5.10E-05 0.003827199
hsa-miR-374a 3.05E-06 0.000228435 hsa-miR-375 8.42E-05 0.005411178
hsa-miR-383 6.17E-06 0.000396473 hsa-miR-381 0.000137446 0.007731325
hsa-miR-433 2.21E-05 0.001244319 hsa-miR-29b 0.000151785 0.00758924 
hsa-miR-876-3p 2.27E-05 0.001137289 hsa-let-7d 0.000188968 0.008503582
hsa-miR-491-5p 2.28E-05 0.001027239 hsa-miR-363 0.000231325 0.009463298
hsa-miR-758 3.09E-05 0.001262657 hsa-miR-181a 0.000238667 0.008949995
hsa-miR-369-5p 6.36E-05 0.002386368 hsa-miR-29a 0.000248598 0.008605322
hsa-miR-128 8.65E-05 0.00299527 hsa-miR-645 0.000397226 0.012767979
hsa-miR-382 0.000100962 0.003245214 hsa-miR-27b 0.000445602 0.013368052
hsa-miR-149 0.000134202 0.004026065 hsa-miR-15a 0.000486256 0.013675949
hsa-miR-139-3p 0.000144353 0.004059936 hsa-miR-130b 0.000629508 0.01666346 
hsa-miR-221 0.000217727 0.005763365 hsa-miR-199b-5p 0.000807868 0.020196708
hsa-let-7d 0.000251463 0.006286567 hsa-miR-638 0.000986321 0.022192214
hsa-miR-17 0.000288892 0.006842176 hsa-miR-154 0.001076479 0.023067405
hsa-miR-625 0.000302578 0.006808014 hsa-miR-125b 0.001155641 0.023638117
hsa-miR-301b 0.000328164 0.007032081 hsa-miR-128 0.001283273 0.025107512
hsa-miR-379 0.000345211 0.007061142 hsa-miR-551b 0.001321223 0.024772937
hsa-miR-137 0.000347959 0.006807901 hsa-miR-101 0.00140852 0.025353365
miR-132 0.000366338 0.006868842 hsa-miR-190 0.001414796 0.024486853
hsa-miR-127-3p 0.00037765 0.006797695 hsa-miR-7 0.001432408 0.023873471
hsa-miR-30d 0.000399474 0.006913968 hsa-miR-652 0.001498502 0.024083072
hsa-miR-181a 0.000506896 0.008448264 hsa-miR-383 0.002098629 0.032564936
hsa-miR-222 0.000524302 0.008426275 hsa-miR-944 0.002110324 0.031654864
hsa-miR-31 0.000648658 0.010065386 hsa-miR-324-5p 0.002298239 0.033361538
hsa-miR-504 0.000698815 0.010482221 hsa-miR-376a 0.002430835 0.034183614
hsa-miR-323-3p 0.000733074 0.010641401 hsa-miR-221 0.002745997 0.037445407
hsa-miR-124 0.000775849 0.010910377 hsa-miR-146b-5p 0.003182978 0.040924004
hsa-miR-19b 0.000830577 0.011326052 miR-132 0.00347397 0.04342463 
hsa-miR-107 0.000862912 0.011094586 hsa-miR-23b 0.00425432 0.051741735
hsa-miR-130b 0.000992179 0.012067047 hsa-let-7g 0.004530666 0.053652619
hsa-miR-19a 0.001025144 0.012139861 hsa-let-7b 0.005117286 0.059045611
hsa-miR-873 0.001030152 0.011886371 hsa-miR-302b 0.005685057 0.063956895
hsa-miR-668 0.001086738 0.012225805 hsa-let-7f-1 0.005703816 0.062602863
hsa-miR-26b- 0.001353912 0.014860005 hsa-miR-629 0.006871687 0.073625221
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hsa-miR-20a 0.00142597 0.015278249 hsa-miR-323-3p 0.006934593 0.072571319
hsa-miR-410 0.001737357 0.018181641 hsa-miR-760 0.007681425 0.078560033
hsa-miR-26b 0.001815556 0.018568187 hsa-miR-488 0.009298286 0.09298286 
hsa-miR-212 0.001822526 0.01822526 hsa-miR-106b 0.009383915 0.091799173
hsa-miR-487b 0.001844204 0.018041125 hsa-miR-125a-5p 0.010667947 0.102139922
hsa-miR-7-2 0.001936764 0.018157166 hsa-miR-192 0.011604207 0.108789441
hsa-miR-134 0.002043478 0.018766639 hsa-miR-329 0.011777834 0.108163785
hsa-miR-154 0.00212492 0.019124283 hsa-miR-433 0.012391434 0.111522907
hsa-miR-432 0.002165518 0.019107509 hsa-miR-125b-2 0.012662248 0.111725718
hsa-miR-187 0.002400987 0.020777775 hsa-miR-767-5p 0.013442403 0.116328484
hsa-miR-545 0.002409938 0.020461736 hsa-miR-190b 0.013555506 0.115093919
hsa-miR-140-5p 0.002457065 0.020475539 hsa-miR-499-5p 0.013734372 0.114453097
hsa-miR-589 0.002963526 0.024247028 hsa-miR-524-3p 0.014667599 0.12000763 
hsa-miR-30b 0.003328908 0.026750157 hsa-miR-511 0.016407957 0.131849657
hsa-miR-331-3p 0.003512267 0.027728422 hsa-miR-545 0.01641655 0.129604343
hsa-miR-129-5p 0.003585407 0.027817809 hsa-miR-425 0.016625385 0.128990055
hsa-miR-488 0.003763286 0.028224643 hsa-miR-410 0.016702412 0.127391278
hsa-miR-27b 0.00379517 0.027997158 hsa-miR-576-3p 0.017023068 0.127673007
hsa-miR-768-3p 0.004159619 0.030190784 hsa-miR-423-5p 0.017471719 0.128889728
hsa-miR-329 0.004182062 0.029871869 hsa-miR-21 0.018068245 0.131140491
hsa-miR-125b 0.004221457 0.029682119 hsa-miR-130a 0.018438001 0.131700004
hsa-miR-138-1 0.004250934 0.029429547 hsa-miR-16 0.018553591 0.130454935
hsa-miR-135b 0.004344852 0.029623993 hsa-miR-30d 0.018783146 0.130037161
hsa-miR-642 0.004676412 0.031408734 hsa-miR-32 0.019813957 0.135095162
hsa-miR-146b-5p 0.004690498 0.031040061 hsa-miR-580 0.020141182 0.135276595
hsa-miR-380- 0.005258469 0.034294365 hsa-miR-601 0.020363445 0.134758094
hsa-miR-454 0.00532704 0.034245255 hsa-miR-17 0.021102795 0.137626925
hsa-miR-381 0.005360538 0.033975241 hsa-miR-150 0.021833272 0.140356748
hsa-miR-522 0.005443776 0.034023599 hsa-miR-218 0.022877329 0.144997153
hsa-miR-374b 0.00557577 0.034371184 hsa-miR-519b-3p 0.022904722 0.143154514
hsa-miR-181a 0.005825974 0.03542822 hsa-miR-520c-3p 0.022980235 0.141658982
hsa-miR-574-3p 0.006279842 0.037679055 hsa-miR-181c 0.023550566 0.143212898
hsa-miR-511 0.006411416 0.037962334 hsa-miR-126 0.023846916 0.143081498
hsa-miR-125b-2 0.006683615 0.039060086 hsa-miR-222 0.024033646 0.142304483
hsa-miR-192 0.006909738 0.039863874 hsa-let-7e 0.02423134 0.141611728
hsa-miR-539 0.007108796 0.040493139 hsa-miR-628-5p 0.024606605 0.14196118 
hsa-miR-24 0.007121175 0.040056609 hsa-miR-570 0.025516492 0.145347104
hsa-miR-519a 0.007646843 0.042482463 hsa-miR-367 0.025769556 0.144953753
hsa-miR-499-5p 0.007764333 0.042609143 hsa-miR-199a-5p 0.028031925 0.155732919
hsa-miR-363 0.008049603 0.043642425 hsa-miR-513-3p 0.029155971 0.160002278
hsa-miR-106a 0.008060527 0.043181395 hsa-miR-124 0.03060438 0.165927362
hsa-miR-124 0.008224747 0.043542777 hsa-miR-125b-1 0.030717468 0.164557867
hsa-miR-520c-3p 0.008345135 0.043666404 hsa-miR-409-5p 0.031706125 0.167855955
hsa-miR-33a 0.009124257 0.04719443 hsa-miR-181a 0.032043621 0.167670112
hsa-miR-302b 0.009272412 0.047415743 hsa-miR-539 0.032047688 0.165763904
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hsa-miR-495 0.009300501 0.047025003 hsa-miR-483-5p 0.03279019 0.167677109
hsa-miR-135a 0.009397144 0.046985718 hsa-miR-149 0.033489805 0.169330476
hsa-miR-214 0.009581388 0.047380491 hsa-miR-340 0.033559104 0.167795519
hsa-miR-100 0.009910584 0.048475682 hsa-miR-454 0.034372997 0.16997636 
hsa-miR-449a 0.010159944 0.048638028 hsa-miR-139-5p 0.036967052 0.1808171 
hsa-miR-203 0.010247505 0.048540811 hsa-miR-337-5p 0.037416661 0.181048359
hsa-miR-616 0.010819335 0.050715633 hsa-miR-26a 0.037992102 0.181877084
hsa-miR-34c-5p 0.010913185 0.050628177 hsa-miR-487a 0.038285127 0.181350603
hsa-miR-423-5p 0.010934061 0.050207423 hsa-miR-744 0.038443157 0.180202297
hsa-miR-570 0.01104799 0.050218139 hsa-miR-382 0.038935506 0.180628636
hsa-miR-125b-1 0.012166453 0.054749038 hsa-miR-639 0.039161178 0.179821736
hsa-miR-374a 0.012408073 0.055283492 hsa-miR-487b 0.040632039 0.184691088
hsa-miR-370 0.012685187 0.055964062 hsa-miR-106b 0.042704267 0.1921692 
hsa-miR-23b 0.013017696 0.056873428 hsa-let-7a 0.043227806 0.192599134
hsa-miR-139-5p 0.013042298 0.056433018 hsa-miR-551b 0.043487648 0.19185727 
hsa-miR-708 0.01310181 0.056150616 hsa-miR-378 0.044108067 0.192705149
hsa-miR-154 0.013147054 0.055812966 hsa-miR-146a 0.044507398 0.192580087
hsa-miR-221 0.013158439 0.055339228 hsa-miR-143 0.046226889 0.198115237
hsa-miR-625 0.013401781 0.055840755       
hsa-miR-579 0.013411907 0.055370259       
hsa-miR-25 0.013662936 0.055893829       
hsa-miR-184 0.013750648 0.055745869       
hsa-miR-769-5p 0.01423937 0.057211754       
hsa-miR-106b 0.014408797 0.057380166       
hsa-miR-153 0.014834114 0.058555711       
hsa-miR-409-5p 0.014855343 0.058129602       
hsa-miR-16 0.015220626 0.059045531       
hsa-miR-876-5p 0.015535925 0.059753558       
hsa-miR-455-5p 0.016015984 0.061077905       
hsa-miR-15b 0.016107474 0.060910615       
hsa-miR-340 0.016712411 0.062671541       
hsa-miR-133b 0.016893353 0.062826519       
hsa-miR-767-5p 0.0169668 0.06258246       
hsa-let-7i 0.017315253 0.063348486       
hsa-miR-505 0.017507328 0.06353466       
hsa-miR-152 0.017652969 0.063550689       
hsa-miR-340 0.017886019 0.06387864       
hsa-miR-517c 0.018061689 0.063998112       
hsa-miR-636 0.01830796 0.064363921       
hsa-miR-9 0.018573469 0.064791172       
hsa-miR-485-3p 0.018634558 0.064504238       
hsa-miR-376a 0.018706273 0.064258188       
hsa-miR-142-5p 0.019237274 0.065581617       
hsa-miR-628-5p 0.019404486 0.065654275       
hsa-miR-375 0.020726729 0.069604687       
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hsa-miR-335 0.021411324 0.071371081       
hsa-miR-15a 0.0215993 0.071468271       
hsa-miR-518f 0.022494694 0.07388768       
hsa-miR-885-5p 0.022844241 0.074492089       
hsa-let-7g 0.022885915 0.074091092       
hsa-miR-564 0.022948359 0.073762583       
hsa-miR-590-5p 0.023176219 0.073966656       
hsa-miR-216b 0.023301759 0.073843602       
hsa-miR-29b-2 0.023414813 0.073682978       
hsa-miR-141 0.024028348 0.075088587       
hsa-miR-181a-2 0.024105331 0.074809646       
hsa-miR-500 0.024908348 0.076772307       
hsa-miR-886-3p 0.025183657 0.077092829       
hsa-miR-551b 0.02526875 0.07683066       
hsa-miR-199b-5p 0.026235974 0.079236164       
hsa-miR-545 0.026715191 0.080145573       
hsa-miR-197 0.027685816 0.082507398       
hsa-miR-338-3p 0.02830659 0.083802405       
hsa-miR-629 0.028664401 0.084307061       
hsa-miR-219-5p 0.02882042 0.084215513       
hsa-miR-20a 0.029092809 0.084462994       
hsa-miR-151-3p 0.029632088 0.085477177       
hsa-miR-93 0.029722787 0.085192702       
hsa-miR-105 0.029745672 0.084718685       
hsa-miR-671-3p 0.029926435 0.084697457       
hsa-miR-185 0.03060288 0.086070599       
hsa-miR-27b 0.030820071 0.086143055       
hsa-miR-582-5p 0.031281924 0.086894232       
hsa-miR-200b 0.031398359 0.086682585       
hsa-miR-328 0.032423273 0.088966298       
hsa-miR-32 0.032447305 0.08849265       
hsa-miR-508-3p 0.033810109 0.091653909       
hsa-miR-526b 0.034443733 0.092812455       
hsa-let-7e 0.035764282 0.095797183       
hsa-miR-639 0.036242873 0.096504692       
hsa-miR-378 0.036473565 0.096547671       
hsa-miR-766 0.037043755 0.097483567       
hsa-miR-411 0.03894087 0.101880183       
hsa-miR-490-3p 0.040434477 0.105176384       
hsa-miR-192 0.041519216 0.107377282       
hsa-miR-194 0.042170799 0.108439198       
hsa-let-7a 0.042609673 0.108945186       
hsa-miR-589 0.042926638 0.109135519       
hsa-miR-598 0.043765713 0.110643657       
hsa-miR-942 0.044128169 0.110936738       
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hsa-miR-486-5p 0.044362633 0.110906582       
hsa-miR-219-2-3p 0.044711817 0.111161976       
hsa-miR-335 0.04519806 0.111753446       
hsa-miR-655 0.045936001 0.112957381       
hsa-miR-188-5p 0.048838855 0.119442851       
hsa-miR-877 0.049143901 0.11953922       
 
 
